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Molecular Biology

Characterization of Antibiotic Resistance Mutations m Borrelia burgdorferi
Director: D. Scott Samuels
This study has identified and characterized five Borrelia burgdorferi naturally
occurring mutations conferring resistance to spectinomycin, kanamycin,
gentamicin or streptomycin. These antibiotics target the small subunit o f the
ribosome, which catalyzes protein synthesis. A naturally occurring coumermycin
Ai-resistant mutant has also been characterized. Four other B. burgdorferi
mutants have been created using site-directed mutagenesis conferring resistance
to coumermycin Aj. Coumermycin Ai targets the B subunit of DNA gyrase,
which catalyzes DNA supercoiling.
16S rRNA mutations, A l 185G and Cl 186U, homologous to Escherichia coli
nucleotides 1191 and 1192, confer 1500-fold and 2500-fold resistance,
respectively, to spectinomycin. These mutations appear in a population of B.
burgdorferi wild-type parental strain B31-A at a high frequency o f 6 x 10'6. After
100 generations in competition with wild-type B31-A, 18% of the cells in a B31A+ C 1186U culture was mutants and 8% of the cells in a B31-A+ A l 185G
culture were mutants. A 16S rRNA A1402G mutation confers over 100-fold
resistance to kanamycin and gentamicin. These mutants appear at a frequency of
1 x 10'8 in a population of B31 and are unable to compete with B31-A after 100
generations. Two streptomycin-resistant mutations were identified in the S12
ribosomal protein. A K88R mutation conferred seven-fold resistance and a K88E
mutation conferred 10-fold resistance to streptomycin. Both exhibited only the
streptomycin-resistant, SmR, phenotype. The frequency of the streptomycinresistant mutants was 3 x 10"9 and the K88E mutant was unable to compete with
B31-A at 100 generations.
Coumermycin Ai-resistant mutants were constructed with amino acid
substitutions in gyrase B o f T162F, T162L, T162M and T162S. These mutants
were from 5 to 6000-fold resistant to coumermycin A \. The naturally occurring
T162I mutant was 420-fold resistant to coumermycin Ai.
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Chapter 1
Introduction

1.1 Borrelia burgdorferi
Borrelia burgdorferi is a tick-bome pathogen that causes Lyme disease in
humans (1). Although the entire genome of B. burgdorferi has been sequenced
(2) a limited number of molecular tools are available to use in manipulating this
genome (3). An important factor in developing these tools is choosing selectable
markers that allow molecular biologists to identify clones of interest. A high
mutation rate conferring resistance to an antibiotic used for selecting clones, or a
high frequency in the population of organisms resistant to the antibiotic of choice,
interferes with selection. In addition to the utility for molecular manipulation,
many microorganisms have become resistant to a host of antibiotics that are, or
have been, medically significant (4, 5, 6). Studies on the mechanisms of how
resistance is acquired and maintained may further the understanding o f how to
avoid or eradicate resistant organisms that were once susceptible to a class of
antibiotics.
The genome of B. burgdorferi is unusual for bacteria. It has a number of
linear plasmids with covalently-closed hairpin loops at the telomeres and several
circular plasmids in addition to a single linear 910 kb chromosome (2). Within
the linear chromosome are two copies of the 23 S and 5S rRNA genes and a single
copy o f the 16S rRNA gene (7, 8). The secondary structure and sequence of the
B. burgdorferi 16S rRNA is nearly identical to that of many bacteria including

1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Escherichia coli and Thermus thermophilus and to eukaryotic chloroplast 16S
rRNA found in Chlamydomonas and Nicotiana (9). These sequence and
structural homologs are particularly helpful in providing clues of where possible
mutations that confer resistance to a particular antibiotic would be located in the
B. burgdorferi genome.
Many antibiotics, such as spectinomycin and the aminoglycosides, target
bacterial ribosomes preventing translocation of tRNAs during translation
(spectinomycin) or causing errors in accurately selecting cognate tRNAs
(aminoglycosides) (10,11,12, 13). Other antibiotics, such as the coumarins,
prevent DNA gyrase from introducing negative supercoiling, which is necessary
for normal replication, recombination, and transcription. Some mutations can
prevent binding by these antibiotics or compensate for antibiotic binding, while
maintaining or restoring near normal levels of ribosomal or DNA gyrase function.
A short review of ribosomal function and a literature review of mutations that
confer resistance to these antibiotics will assist in understanding the results of this
study, which identified the mechanisms of antibiotic-resistance in Borrelia
burgdorferi.

1.2 Ribosomes
In E. coli, a typical prokaryote and model organism for ribosomal
function, the 16S rRNA combines with 21 proteins to form the 30S ribosomal
subunit. The 23 S and 5S rRNAs combine with 31 proteins to form the 5OS
ribosomal subunit (10). These subunits assemble to form a 70S ribosome during

2
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protein synthesis. Initiation of protein synthesis occurs when translation initiation
sequences on mRNA bind by complementary sequences along the 16S rRNA of
the 30S subunit. An initiation complex forms when initiation factors, f-MettRNAfMet (the initiator tRNA), the 3OS subunit, mRNA and the 5OS subunit
assemble (10). The peptidyl sites (P-site) located on both the 30S and 50S
subunits are occupied by f-Met-tRNAfMet upon assembly of the initiation complex
(10). Elongation o f the polypeptide chain begins as a cognate tRNA recognizes
the correct codon on mRNA, occupies the A-site (which is also comprised of
portions of both ribosomal subunits), and forms a peptide bond with the
polypeptide chain attached to tRNA in the P-site (peptidyl tRNA) of the 70S
ribosome (10). The now uncharged (no amino acid) peptidyl tRNA is released as
the A-site tRNA (aminoacyl tRNA) possesses the polypeptide chain becoming the
peptidyl tRNA. Translocation occurs when the aminoacyl tRNA with the
polypeptide chain in the A-site moves to the P-site with the assistance of
elongation factor G and the expenditure of energy provided by hydrolyzed GTP
(10). These procedures are repeated until the polypeptide is formed and
translation terminates when the ribosome reaches a stop codon on mRNA. A
review of this process is illustrated in Figure 1.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1. Basic ribosome structure and the translation cycle. (A) 16S rRNA is
part of the 30S subunit. (B) An initiation complex forms when initiation factors
(IF2), f-Met-tRNAfMet (the initiator tRNA), the 30S subunit, mRNA and the 50S
subunit assemble. (C) The E (exit) site, P (peptidyl) site, and A (aminoacyl) site
on the 70S ribosome with f-Met-tRNAfMet. (D) Selection o f cognate tRNA. A
charged aminoacyl tRNA binds at the A-site. (E) Translocation of the peptidyl
tRNA to the E-site and the aminoacyl tRNA to the P-site after a peptide bond was
formed between the peptidyl tRNA amino acid and the aminoacyl tRNA amino
acid.
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1.3 Antibiotic Resistance
There are only a few reports of antibiotic resistance in B. burgdorferi and
only one example of resistance to an antibiotic that targets the ribosome (14,15).
B. burgdorferi strain N40 was shown to be >3000 times more resistant to the
macrolide erythromycin than strain B31-A (14). In vitro experiments have shown
B. burgdorferi to be susceptible to this antibiotic (16,17), which contrasts with
clinical trials that were ineffective in treating Lyme disease in humans and
animals (18, 19). Differences in the physiology of B. burgdorferi when grown in
culture instead o f a host have been proposed as a possible mechanism for this
discrepancy (19). Although the mechanism o f resistance has not been identified in
strain N40, erythromycin-resistant clones selected on solid medium showed
changes in colony morphology and lack o f growth in liquid medium indicating
resistance may be due to changes in metabolism (14). Metabolic changes
associated with antibiotic resistance and affecting normal functions such as
colony morphology and size, cell aggregation, and cell adhesion have been
identified previously in Pseudomonas aeruginosa (20). Sequencing the 23 S
rRNA gene revealed that the mechanism of erythromycin resistance conferring
resistance in B. burgdorferi strain N40 is not a mutation in the 23 S rRNA, a
common site in other bacteria such as Streptococcus pneumoniae (21). An
A2059G mutation in the 23S rRNA of S. pneumoniae conferred resistance to
erythromycin, and as the number of alleles with this mutation increased, the level
o f resistance also increased.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.4 Spectinomycin Resistance
Spectinomycin is an aminocyclitol antibiotic produced by several species
of Streptomyces, including S. flavopersicus and S. glebosus (22), which targets the
30S ribosomal subunit of many gram-negative bacteria. In E. coli and T.
thermophilus, spectinomycin blocks elongation of the polypeptide during protein
synthesis by preventing the translocation of the peptidyl tRNA from the A-site to
the P-site (11,12,13). The antibiotic inhibits the activity of elongation factor G,
which binds GTP and promotes translocation of the ribosome along mRNA (11,
13). Associated with the translocation process is helix 34 (H34, Figure 2) o f 16S
rRNA that comprises a portion of the A-site. Rotation of H34 and other elements
of the 16S rRNA head enable the movement o f mRNA along the ribosome and
subsequently the translocation of tRNA from the A-site to the P-site. This
movement is inhibited by the rigid spectinomycin molecule when it forms
hydrogen bonds with several bases including G1064 and C l 192 homologous to B.
burgdorferi 1058 and 1186, respectively, in the minor groove o f H34 (11, 12, 23).
Translocation o f tRNA not only involves movement o f H34 but possibly H35 and
H38 as well (11). Spectinomycin binding stabilizes H34 and could sterically
hinder its movement, or prevent conformational changes necessary for
translocation (11).
E. coli has been shown to be resistant to spectinomycin when nucleotide
1064 or the base-paired partner at 1192 in H34 of the 16S rRNA are mutated (12).
T. thermophilus is also spectinomycin resistant when the base-pair G1064 and
Cl 192 are mutated (11). (E. coli numbering will be used throughout the text

6
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unless otherwise noted.) Currently, most mutations at these sites are hypothesized
to reduce the overall stability of H34 restoring the movement necessary for the
translocation of tRNA even while spectinomycin is bound (11). Thermodynamic
studies of all mutations at these sites have been shown to reduce the stability of
H34 with the exception o f the Cl 192G mutant (12,24,25). A C l 192G mutation
combined with the compensatory mutation, G1064C, actually increases the
stability o f H34 (25) and are accompanied by a five-fold decrease in growth rates
when compared to wild-type (12). This double mutant interferes with the
assembly o f the 70S ribosome, reducing ribosomal activity and causing decreased
growth rates in E. coli (11,12). This might be particularly important for B.
burgdorferi since it has only one copy of the 16S rRNA gene (rrs) compared to
the seven copies in E. coli. The Cl 192G and G1064C mutations may prevent the
assembly o f functional ribosomes, and consequently inhibit growth o f B.
burgdorferi since it lacks another 16S rRNA. Analysis of translational efficiency,
using chloramphenicol acetyl transferase (CAT) as a reporter, with the mutations
G1064A, C, or U and C l 192U showed little effect on ribosomal activity in E. coli
in the presence of spectinomycin indicating these mutations have little effect on
growth rates (12). By comparison, CAT activity for the Cl 192G-G1064C double
mutant was 20% of normal, which explains the observed decrease in growth rates
(12). In addition to the changes observed in ribosomal activity and growth rates,
differences in levels of spectinomycin resistance by different base substitutions
have also been observed. A C l 192A mutation gives low levels of resistance while

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

substitutions at this site to U or G give high levels of resistance to spectinomycin
(24).
Mutations at sites 1191 and 1193 in the chloroplast 16S rRNA o f C.
reinhardtii and A. tabacum confer resistance to spectinomycin for these
eukaryotic organisms as well (26,27). As with E. coli mutants, different levels of
resistance correspond to mutations at different sites. A G1193A mutation confers
low-level resistance to spectinomycin while A l 191G and A l 191C mutants result
in high-levels o f resistance in C. reinhardtii (26).
Mutations that result in amino acid substitutions in the S5 protein o f the
3OS ribosomal subunit confer resistance to spectinomycin in E. coli and T.
thermophilus. Two different strains of E. coli have been shown to be resistant to
spectinomycin when serine of the VSK tripeptide (residues 20-22) is mutated to
proline creating a S21P substitution (27,28,29). Although S5 does not directly
interact with the antibiotic (11, 28), resistance is probably due to destabilization of
the tertiary structure formed by interactions of the 16S rRNA with the protein (11,
30). Structural changes in the S5 protein may cause a shift in the structure of the
upper stem o f helix 34 making it inaccessible to spectinomycin (11).
Spectinomycin is not used as an antibiotic to treat Lyme disease but is
currently used to treat infections by strains of Neisseria gonorrhoeae. Many
antibiotic-resistant strains of A. gonorrhoeae have emerged in the past few years,
but spectinomycin continues to be effective in treating gonococcal infections
world-wide (31, 32, 33). However, clinical isolates of A. gonorrhoeae that are

8
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spectinomycin-resistant have been identified. As expected, these resistant strains
had G1064C and Cl 192U mutations in the 16S rRNA (34).

1.5 Kanamycin and Gentamicin Resistance
Kanamycin and gentamicin are aminoglycosides produced by
Micromonospora and Sirepiomyces species. They are both 2-deoxystreptamine
antibiotics belonging to the 4, 6-disubstituted class of aminoglycosides (35). The
two antibiotics are structurally similar with the main difference of two additional
amine groups on gentamicin (35). Kanamycin is of particular interest since many
organisms have become resistant to this antibiotic by mutations in their 16S rRNA
genes or by possessing genes whose products catalyze acetylation,
phosphorylation or methylation of aminoglycosides, or by modifications to the
16S rRNA gene (36, 37, 38). Both antibiotics cause miscoding of mRNA upon
binding to the 16S rRNA (35, 36). These antibiotics bind to the major groove of
helix 44 (Figure 2) in a pocket formed by the non-canonical base-pairing of
A1408 and A1493 and the bulged nucleotide A1492 (39). This region
encompasses a portion of the A-site and includes the universally conserved
A 1492 and A 1493 sites that are essential for E. coli ribosomal function and
viability (39,40). Gentamicin and kanamycin form several hydrogen bonds along
the major groove of H44 including G1494, U1495, G1405 and U1406 (39, 41).
Hydrogen bonds are also formed with A1408 (G1408 in eukaryotic organelles)
and stacks against G1491 causing the phosphate backbone of A1492 and A1493
to flip out and lock into this position (11, 36). In this locked position, the affinity

9
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for cognate and noncognate tRNAs at the A-site is increased causing errors in
reading mRNA transcripts (11). In the absence of antibiotic, this region would be
free to rotate during the decoding step, reducing or eliminating translational errors
( 11).
A mutation at site U1406 or A1408 confers resistance to gentamicin and
kanamycin in E. coli (36). A U1406A mutation in E. coli confers low level
resistance to kanamycin and gentamicin while increasing the culture doubling
time from 60 to 90 minutes (36). The slower growth rate, which is typical of
hyperaccuracy, would indicate there is some interference of ribosomal function.
Hyperaccuracy occurs when the ribosome becomes too selective for tRNAs,
slowing down elongation of polypeptides and subsequently growth. An A1408G
mutation in E. coli causes no change in the doubling time and apparently does not
interfere with ribosomal function, but does confer high levels of resistance to
these antibiotics (36). Footprinting studies have demonstrated that resistance in
these two mutants results from decreased binding affinity of kanamycin and
gentamicin to H44 (36,42). This inability to bind is caused by the distortion
created in the binding pocket as a result o f the base substitutions at either 1406 or
1408(42).
Many microorganisms can become kanamycin and gentamicin-resistant.
For example, an A1408G mutation and several C1409 mutations confer high
levels of resistance (>500 fold) to kanamycin in several species of Mycobacterium
(43, 44). An A1408G mutation in C. reinhardtii resulted in high levels of

10
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resistance to kanamycin, while a C1409U mutation confers lower levels of
resistance (26).

1.6 Streptomycin Resistance
The aminoglycoside streptomycin, like spectinomycin, is an antibiotic
produced by Streptomyces species. This antibiotic disrupts translational accuracy
by increasing the affinity for noncognate aminoacyl tRNA molecules and
interfering with the ability to accurately proofread during translation (45,46).
This error-prone activity is induced when streptomycin forms hydrogen bonds at
several sites along the 16S rRNA phosphate backbone and the ribosomal S12
protein (11, 47). In E. coli and T. thermophilus, studies involving mutagenesis,
cross-linking, and crystallography have identified several bases in the 16S rRNA
and a residue in S12 as binding sites for streptomycin (11,48,49, 50). These sites
include 16S rRNA C526 and G527 in the 530 loop located within H18, A913 and
A914 of the 900 stem loop in H27, C l490 and G1491 of H44, and U14 in the 16S
5' end (Figure 2) (11). The single contact in S12 is at residue K45. Single
mutations in the 16S rRNA or the S12 gene, rpsL, in E. coli have been shown to
cause resistance to streptomycin (47,48,49, 51). These include, but are not
limited to, the 16S rRNA sites 523, 885-890, and 910-912, and the S12 residue
K45. Mutations at homologous sites in the 16S rRNA and the S12 protein also
confer resistance to streptomycin in many other organisms (52, 53, 54, 55). A
K88N mutation in the S12 protein of Mycobacterium tuberculosis (52) and a
C912U mutation in the chloroplast 16S rRNA of the eukaryote Euglena gracilis

11
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(53) have been shown to confer streptomycin resistance in these organisms.
Wild-type 18S rRNA in yeast has a U at site 912 that confers natural resistance to
streptomycin. When the reverse mutation is made, U912C in yeast 18S rRNA,
these organisms also become susceptible to the antibiotic (56).
Mutations in the 16S rRNA and S12 protein can produce several different
E. coli phenotypes with respect to streptomycin resistance. These phenotypes
result from mutations o f sites in the helix 27 “accuracy switch” (49). Helix 27 has
been proposed to have two possible base-pairing patterns during translation.
Bases 910-912 are paired with bases 885-887 in what is termed the ribosomal
ambiguity or ram state, which has a high affinity for tRNA (49, 57, 58).
Transient switching o f the base pairing o f 910-912 to bases 888-890 moves the
16S rRNA into the restrictive or proofreading state that lowers its affinity for
tRNA (49). In the restrictive state, the S-tum motif of H27 that was present in the
ram state is disrupted, changing the packing between H27 and H44. This change
in conformation by H27, which contacts several other helices, probably causes
conformational adjustments by these adjacent helices as well (11). Chemical
protection experiments show that residues of these helices are more chemically
reactive in the restrictive state, which is consistent with the proposed
conformational changes (11). The contacts that S12 makes in this region probably
facilitate the switch mechanism in H27 (49). Streptomycin binding is
hypothesized to stabilize the area and prevent switching to the restrictive state,
increasing the affinity for noncognate tRNA and, consequently, errors in
translation (11).

With the addition of streptomycin, the 16S rRNA is locked into

12
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the error-prone ram state and unable to switch to the hyperaccurate restrictive
state to proofread and eject non-cognate tRNAs (11). The presence of the S 12
protein is also believed to stabilize this region. An S12 mutation may destabilize
the region compensating for the increased stability conferred by streptomycin
(11). This possibility would allow the ribosome to switch to the restrictive state,
edit the translational errors and function fairly normally even while bound to
streptomycin (11). This streptomycin-resistant E. coli phenotype is designated
SmR (59). A mutation at one of the previously mentioned sites in 16S rRNA,
destabilizing the region, also produces a SmR phenotype (11). Mutations that
produce the SmR phenotype do not provide cross-resistance to other
aminoglycosides such as kanamycin and gentamicin (60).
Another streptomycin phenotype results from mutations in the small
subunit proteins or multiple mutations to 16S rRNA. This phenotype is called
streptomycin-dependent and is designated SmD (61). Mutations in the S4, S5 and
S12 proteins or multiple mutations in 16S rRNA force the ribosome to remain
predominately in a restrictive state. Streptomycin binding stabilizes the ram state
restoring ribosomal function by permitting the ribosome to switch between the
error-prone ram state and the hyperaccurate restrictive state (11). The SmD
phenotype is cross-resistant to kanamycin and gentamicin, which provides another
method for verifying the SmD phenotype (60).
Specific mutations to the S12 protein have been shown to produce either
the SmR or SmD phenotypes in several organisms, including is. coli, T.
thermophilus and Salmonella typhimurium (62, 63, 64). In T. thermophilus,
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single mutations in the rpsL gene resulting in amino acid substitutions P41S,
K42R, K88E or K88R in the S12 protein resulted in a SmR phenotype (62). Each
of these mutations gave high levels of resistance to streptomycin with the P41S
mutant being about half as resistant as the others. Culture doubling times for each
of the mutants were increased over the wild-type. K88E had the longest increase
in doubling time at 90 minutes, while K88R had the smallest increase at 56
minutes compared to the doubling time for wild-type T. thermophilus o f 50
minutes (62). The frequency o f these mutants was reported to be 10'7(62), which
is about three orders of magnitude more frequent than the homologous mutations
m E . coli (2 x 10‘10) (63,65).
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1.7 Coumermycin Ai Resistance
Coumermycin Ai is an antibiotic in the coumarin family produced by
Streptomyces species (66). This antibiotic targets DNA gyrase (67), a type II
topoisomerase that introduces negative supercoiling in DNA, which relieves
torsional stress during replication or transcription (68). Gyrase is an A 2 B 2 tetramer
encoded by two genes, gyrA and gyrB. Gyrase A catalyzes the breakage and
reunion of double-stranded DNA and gyrase B contains the ATP binding site
involved in ATP hydrolysis (68). Coumermycin Ai binds to gyrase B inhibiting
ATP hydrolysis and growth (68).
The coumarin antibiotic novobiocin interacts with the universally
conserved residue T165 (T162 in B. burgdorferi) of GyrB in E. coli (69). A
mutation at E. coli T165, and homologous residues in other bacteria, has been
postulated to confer resistance to coumarin antibiotics including coumermycin Ai
(69, 70, 71). Mutations at other residues have also been shown to confer
resistance to coumermycin Ai in several organisms. Several mutations in
Staphylococcus aureus have been shown to confer high resistance to
coumermycin Ai, including a T165N mutation (70). Mutations in Bartonella
bacilliformis at residues G124, R184 and T214 (homologous to G77, R136, and
T 165 in E. coli) are up to five-fold resistant to coumermycin Ai (71). These
residues correspond to residues G74, R133, and T162 in B. burgdorferi. In E.
coli, R136 substitutions, homologous to B. burgdorferi R133, conferred a 10-fold
increase in resistance to coumermycin Ai (72). Three different amino acid
substitutions, R136C, R136H, and R136S, conferred high levels of resistance to

16

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

coumermycin Ai; however, gyrase activity was impaired (72). Mutations in B.
burgdorferi gyrB, which resulted in substitutions at residue R133 to G or I also
provide resistance to coumermycin Ai (73). Furthermore, our laboratory has
found that any amino acid substitution at R133 will confer resistance to
coumermycin At (B. Eggers, C. Eggers and D.S. Samuels, unpublished data.)
The naturally occurring mutations G74S or T162I also have been identified as
conferring resistance to coumermycin Ai in B. burgdorferi (D.S. Samuels,
unpublished data).

1.8 Objectives
The goal of this project was to identify and characterize Borrelia
burgdorferi mutants that are resistant to the antibiotics coumermycin Ai,
spectinomycin, kanamycin, streptomycin, and gentamicin. Mutants resistant to
spectinomycin, streptomycin, kanamycin and gentamicin have been found
resulting from mutations in the genes encoding the 3OS ribosomal subunit,
including the 16S ribosomal RNA and the S12 protein. Mutants resistant to
coumermycin Ai have been constructed by site-directed mutagenesis in the gene
encoding the B subunit o f DNA gyrase. This study focused on genetically
identifying the site o f resistance to these antibiotics and the fitness o f each
antibiotic-resistant mutant.

1.9 Specific Aims
1. Spectinomycin resistant mutants were isolated and characterized. We have
observed naturally occurring mutants o f B. burgdorferi that are resistant to the
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antibiotic spectinomycin. The frequency of mutation was determined by plating
108 and 107 cells of B. burgdorferi in different concentrations of spectinomycin
and counting the number of resistant colonies that appeared on the plate. The
location of the mutation conferring resistance was determined by sequencing the
single gene for the 16S rRNA. Susceptibility assays, measuring the concentration
that inhibits growth of 50% of the cells (IC5 0 ), were used to gauge the level of
resistance to spectinomycin by the resistant mutants. A mutant 16S rRNA gene
that was spectinomycin-resistant was cloned into the vector pBSV2RII and
transformed into wild-type B31-F to determine if resistance in the resulting
merodiploid was recessive or dominant. The pBSV2RII plasmid alone was also
transformed into wild-type B31-A as a control.
2. Aminoglycoside-resistant mutants were isolated and characterized.
We have found mutants resistant to the aminoglycosides streptomycin, kanamycin
and gentamicin. As with the spectinomycin-resistant mutants, plating 108 and 107
cells in 50 pg/ml of the respective antibiotic and counting the number of colonies
that appeared on the plates was done to determine the frequency of these
mutations. The location o f these mutations was determined by sequencing the
gene for the 16S rRNA. Streptomycin-resistant mutations were also found in the
rpsL gene that codes for the S12 protein of the 30S ribosomal subunit.
Susceptibility assays (IC5 0 ) were performed to determine the levels of resistance
to each of the antibiotics. Each antibiotic-resistant mutant was tested for cross
resistance to the other aminoglycosides and spectinomycin to assist in identifying
the cause o f resistance.
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3. The genetic fitness of the spectinomycin- and aminoglycoside-resistant
mutants was assayed. A competition assay was performed to test each of the
mutants against wild-type B. burgdorferi to see if there is a growth advantage or
disadvantage in possessing a particular mutation to one of the antibiotics. We
hypothesized that the high frequency of the spectinomycin-resistant mutants is a
result of no cost or an attenuated cost to the organism that does not significantly
affect growth.
4. Coumermycin Ai-resistant mutants were constructed and characterized.
Random site-directed mutagenesis was used to introduce mutations into the gene
for the B subunit o f DNA gyrase. These mutations change amino acid residue
162 from threonine to any of the other nineteen amino acids. Mutants gyrB genes
were sequenced to identify the amino acid conferring resistance to coumermycin
A\. Each of the coumermycin Ai-resistant clones underwent a susceptibility assay
to determine its level of resistance. A growth assay was done to determine if there
is any significant difference in doubling times for the mutants when compared to
the wild-type.
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Chapter 2
Materials and Methods

2.1 Isolation of Antibiotic-Resistant Mutants
Spectinomycin Resistance. Borrelia burgdorferi strain B31-A was grown
in 10 ml of liquid Barbour-Stoenner-Kelly (BSK-H) medium (Sigma) at 34°C to a
concentration of 108 cells/ml. The cell density was determined by a
spectrophotometer at an optical density (OD) of 600nm. One ml of liquid culture
was centrifuged at 10,000 rpm for 10 minutes, resuspended in one ml of dPBS++
(8.0g NaCl, 0.2g KC1,1.15g Na2H P04,0.2g KH2 P 0 4, O.lg CaCl2, and 0.213g
MgCl2/L) and the optical density at 600nm (OD6 0 0 ) was determined. The OD60o
was multiplied by 1.4 x 109 to calculate the number of cells/ml (74). To determine
the frequency o f spectinomycin resistance cells in the B. burgdorferi population
o

and to estimate the resistance levels of these strains, one ml (10 cells) of this
culture was plated in semi-solid BSK medium (75) with spectinomycin (Sigma) at
concentrations of 1.5 pg/ml, 6.0 pg/ml, and 30 pg/ml. 100 pi (107 cells) were
plated at the same spectinomycin concentrations. The plates were incubated at
34°C for 11 days before colonies appeared. This procedure was repeated
independently seven times. Seven spectinomycin-resistant colonies were isolated
from the plates and grown in 10 ml o f BSK medium containing 1.5 pg/ml o f

spectinomycin, until 108 cells were present in the growth medium. DNA was
extracted from each of the clones grown in liquid BSK as previously described
(74). Spirochetes from the 10 ml cultures were centrifuged at 10,000 rpm for 10
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minutes. The pellet was washed with one ml dPBS++ and then resuspended in
200 pi of 50 mM TES (Tris-HCl pH 8, 50 mM EDTA, 15% sucrose). The cells
were lysed by adding 23 pi of 10% sodium dodecylsufate (SDS) and incubated at
37° C for 30 minutes following the addition of 3 pi of proteinase K. The lysate
was extracted using an equal volume of phenol-chloroform-isoamyl alcohol
(25:24:1). DNA was precipitated by adding 8 pi of 5M NaCl and 400 pi of 100%
ethanol and incubated at -20° C. The precipitated DNA was recovered by
centrifugation for 25 minutes at 13,000 rpm, washed with 70% ethanol, and
suspended in 50 pi of 10 mM Tris-HCl (pH 8.0).
The 3' end of the 16S rRNA gene was amplified using 16S 40F and 16S
659R (Table 1) in a polymerase chain reaction (PCR) since this is where known
spectinomycin-resistant mutations are located in other organisms. The reaction
produced a 620 base pair DNA segment. DNA for the sequencing template was
purified using a Qiaquick® PCR purification kit and 15 pi at a concentration of 10
ng/pl were sent with the two primers to the Murdock Molecular Biology Facility
for sequencing. The DNA sequencing template was also amplified using the
same technique to sequence the rpsE gene, which codes for the S5 protein. The
primers used in this PCR reaction were rpsG U322F and rpsE 441R (Table 1).
Aminoglycoside Resistance. The same techniques were used to isolate
and identify streptomycin-, kanamycin-, and gentamicin-resistant mutants, as
described above for the spectinomycin-resistant mutants. BSK plates were made
with 40 pg/ml kanamycin, 35 pg/ml streptomycin, or 30 pg/ml gentamicin. Two
o

sets of plates, one with 10 cells and one with 10 cells, were made using the
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antibiotic concentrations above. This procedure was repeated five times. When
antibiotic-resistant colonies were not consistently isolated on streptomycin and
gentamicin plates at concentrations of 108cells, 109 cells were plated for all three
antibiotics.
Three kanamycin-resistant strains, designated KAN1, KAN3 and KAN4,
were picked and grown as described for spectinomycin-resistant colonies, except
with 40 pg/ml of kanamycin added to each culture tube. DNA was extracted using
standard protocols and the 16S rRNA gene was sequenced for mutations
associated with resistance to kanamycin. The primers 16S 40F and 16S 659R
(Table 1) were used for amplifying the 16S rRNA gene by PCR. The same
procedures used for the spectinomycin-resistant mutants were followed for
purifying the PCR product and sequencing DNA.
One gentamicin-resistant strain was selected and grown in liquid medium
with 25 pg/ml gentamicin. From this 10 ml culture, DNA was extracted and
purified for sequencing the 16S rRNA along with the spectinomycin- and
kanamycin-resistant isolates using the same primers. The gentamicin-resistant
strain was designated GEN2.
Four strains from the 35 pg/ml streptomycin plates were isolated and
grown in BSK medium with streptomycin following the previously described
procedures. DNA was extracted following standard protocols from the cultures
designated SmRl, SmR2, SmR3 and SmR4. Due to the possibility that a
mutation in several sites of the 16S rRNA gene might confer resistance to
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streptomycin, the entire gene was sequenced using the primers indicated in Table
1. The location of these primers is shown in Figure 3.
Primers for sequencing the rpsL gene that encodes the S12 protein were a
25 nucleotide reverse primer, rpsG 58R and a 25 nucleotide forward primer, rpsL
U106F (Table 1).

23

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 1. Oligonucleotides used for sequencing the 16S rRNA gene and the
ribosome proteins S5 and S I2.
Oligonucleotide Gene

Sequence (5'-3')

rpsE U322F

rpsE (S5)

AATAAAGGAC AAAAT AGGG

rpsE 441R

rpsE (S5)

CAAAACTAAATCAAATGCC

16SU169F

16S rRNA

AATGACCTAAAATTAAGTCTAA

16S 40F

16S rRNA

TTGTTACGACTTCACCCCCCTC

16S 553F

16S rRNA

TCAAGCCCTGGTAAGGTTCC

16S 659R

16S rRNA

GAGTAT GCTCGC AAGAGT G

16S 993R

16S rRNA

CGTTGTTCGGGATTATTG

16S 1060F

16S rRNA

TCATCACTTTGTCATTTC

16S 1538R

16S rRNA

AAATAACGAAGAGTTTGATCC

BB425 3F

16S rRNA

GGAAGATGAGAGAAGGGAAG

BB426 288F

16S rRNA

AGGATT CGCCTTT GCC AAG

rpsG 58R

rpsL (S I2)

AATTATAT CTGGTAT CAAC AAAAAC

rpsLU106F

rpsL (SI2)

AAAATTAAAGTTAGTGAAAATATCG
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Figure 3. A map o f the annealing sites for each primer. These primers were used
in PCR to amplify 500-600 bp DNA fragments for sequencing the 16S rRNA
gene in B. burgdorferi.
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Coumermycin Ai Resistance. Random site-directed mutagenesis was
performed by Betsy Eggers on the T162 codon o f the gyrB gene by overlap
extension as previously described (76). Two overlapping PCR fragments were
produced from two sets o f primers and then amplified using the flanking primers
of the first reactions. In the first PCR, a 357 nucleotide product was amplified
using a 24 nucleotide forward primer 14IF (5GGCTTTAGCTGGGTTTTGTGATAG-3') and a 27 nucleotide reverse primer
498R/T162X (5'-AAATGAAACCTTNNNCCCCGTAACAGA-3'). A second
497 nucleotide PCR product was amplified using a 27 nucleotide forward primer
472F/T162X (5'- TCTGTTACGGGGNNNAAGGTTACTTTT-3') and a 24
nucleotide reverse primer 969R (5'-GACAGAAATAACAGCTGTAAGCCC-3').
Sites with N (the triplet for T162) had any of the four DNA bases to yield all
possible codons. The purified fragments were then amplified in a second PCR
with the two flanking primers, 141F and 969R, from the initial reactions. The
resulting PCR product, a population of DNA molecules presumably encoding all
codons for residue 162, was purified and 5 pg of the DNA was electroporated into
B. burgdorferi strain B31-A. The transformed culture was plated in semi-solid
BSK medium containing 0.1 pg/ml of coumermycin Ai. (Coumermycin Ai was
first dissolved in DMSO.) Colonies that appeared on the plates in 14 days were
isolated and grown in liquid BSK medium containing 0.1 pg/ml coumermycin Ai.
DNA from the cultures was extracted using standard protocols described above. A
PCR product from the putative mutant gyrB gene was obtained using the primers
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14IF and 969R. The PCR product was purified by ammonium acetate
purification and sent to the Murdock Molecular Biology Facility for sequencing.

2.2 Susceptibility
Spectinomycin Susceptibility. A susceptibility assay was done for each
identified mutant class represented by SPR3 (C1186U) and SPR6 (A ll85G ) as
previously described (74, 77). Cultures were grown in 10 ml of BSK until
108cells/ml was present. From these cultures, 106 cells, determined by an OD60o,
were inoculated into 4 ml of BSK with the following concentrations in pg/ml of
spectinomycin: 0, 60,120,180,240, 300, 360, and 480. After incubating at 34°C
for 72 hours, the cultures were pelleted, resuspended in one ml o f dPBS++ and
the ODeoo was determined. The percent growth was the ODeoo of each sample
compared to the ODeoo of a control with no antibiotic, which was defined as 100%
growth. This procedure was repeated four times for SPR3 and six times for
SPR6. A susceptibility assay was also done for wild-type B. burgdorferi at
spectinomycin concentrations in pg/ml of 0, 0.015,0.03,0.06,0.15, 0.30,0.60
and 1.5. An IC 5 0 , the inhibitory concentration that prevents 50% growth at 72
hours, was used to compare the level of resistance for the mutants. The IC5 0 was
determined by graphing the results in SigmaPlot®. Susceptibility assays were
performed on both spectinomycin-resistant mutants, SPR3 and SPR6, to test for
cross-resistance to the antibiotics streptomycin, kanamycin and gentamicin. 106
cells of each mutant were added to 4 ml of BSK in 10 ml tubes. Antibiotics were
added at the following concentrations in pg/ml and the cultures incubated for 72
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hours at 34°C: streptomycin, 0,0.7,1.8, 3.5, 7,18, 35,70; kanamycin, 0, 0 .8 ,2 ,4 ,
8,20,40, 80; and gentamicin, 0,0.6,1.5, 3, 6,15, 30, 60. An ODeoo was taken for
each culture tube to determine the percent growth and plotted in SigmaPlot® to
determine the IC 5 0 for each mutant in each antibiotic.
To determine if the spectinomycin-resistant mutation was dominant or
recessive, a plasmid expressing the mutant SPR3 (Cl 186U) 16S rRNA gene was
constructed. The plasmid vector, pBSV2RII (Figure 4), was derived from pBSV2
(78) by removing the EcoRl restriction site in open reading frame 2 (ORF2) (S.
Bundle and D.S. Samuels, unpublished data). The 16S rRNA gene was amplified
from SPR3 using the proofreading polymerase KOD. The primers used in the
PCR were 16S U169F and 16S 1538R (Table 1). The approximately 1.7 kb PCR
product includes the entire 16S rRNA gene with its promoter. A 3' adenine
overhang was added to the KOD polymerase PCR product with Taq polymerase.
The overhang reaction was incubated for 10 minutes at 12° C. The adenine
overhang is required for cloning into the pCR2.1-TOPO plasmid. The fragment
was cloned into pCR2.1 using a TOPO TA cloning kit (InVitrogen®). The
pCR2.1 plasmid was transformed into E. coli TOPIO F' cells and extracted from a
10 ml culture using a WizardPlus® mini prep kit. The 1.7 kb 16S rRNA gene
insert was removed from pCR2.1 with EcoRl and ligated into the single £coRI
site o f pBSV2RII, yielding plasmid pVSPR3. The plasmid was transformed into
E. coli DH5a cells, which were grown on 40 pg/ml kanamycin plates to select for
the plasmid. Colonies from the plates were PCR-screened for the presence of the
plasmid and insert using the primers to construct the insert (16S U169F and 16S
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1538R). Plasmid DNA was purified with a Wizard Plus® midi prep kit and 5 pg of
each plasmid was electroporated into competent B. burgdorferi strains B31-F and
B31-A as described (75). These cells were plated in semi-solid BSK medium with
40 pg/ml of kanamycin. When colonies appeared, they were picked and grown in
liquid BSK with 160 pg/ml of kanamycin to continue selective pressure. To verify
the presence o f the pBSV2RH and pVSPR3 plasmids in B31-A and B31-F, DNA
was extracted from the cultures (as previously described) and 2 pg was
transformed back into E. coli DH5a. DH5a was plated on Luria-Bertani plates
with 40 pg/ml kanamycin to screen for colonies with the respective plasmid that
was present in the B31-F DNA extraction.
Susceptibility assays were done as described to determine the level of
resistance conferred by each of the constructed plasmids in wild-type and SPR3
cells. The SPR3 16S rRNA gene was sequenced to check for mutations other than
the C l 186U previously identified as spectinomycin resistant. The 16S U169F
primer was used to sequence the 5' end, BB426 288F was used to sequence the 3'
end, and 553F was used to sequence the center of the SPR3 16S rRNA gene
(Table 1).
To confirm if the SPR3 16S rRNA gene was expressed from the
pBSV2RII plasmid in B31-F, sequencing of cDNA was done using the following
protocols from strain B31-F/pVSPR3 to evaluate the amount of mutant RNA
present in the cell. A culture containing 1010 cells of strain B31-F/pVSPR3 was
centrifuged at 8000 rpm for 15 minutes to pellet the cells. The pellet was
resuspended in 4 ml o f TRIzol™ and incubated for 5 minutes at ambient
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temperature. 1 ml o f chloroform was added and incubated for 2.5 minutes. The
mixture was centrifuged at 10,000 rpm for 15 minutes and the top layer
containing RNA was transferred to a separate culture tube. RNA was precipitated
by adding 1 ml o f isopropanol, mixing by inversion, and incubating at ambient
temperature for 10 minutes. RNA was pelleted by centrifuging at 12,000 rpm for
10 minutes. The pellet was washed with 75% ethanol, centrifuged again and air
dried for 10 minutes. The final RNA pellet was resuspended in 25 ml o f RNasefree water. An OD2 6 0 was taken to determine the concentration o f RNA.
The following procedures were used to obtain cDNA from the RNA. To
insure no DNA was present, the RNA was treated with DNase RQ1 (Gibco). 5 pg
of the treated RNA, 2 pi o f random decamers, and 2 pi of water from a
RETROscript™ RNA kit (Ambion) were incubated at 85°C for 3 minutes. 10 pi
of this reaction was added to 2 pi of 10X RT-Buffer, 4 pi dNTP (25nm), 1 pi
RNase inhibitor and 2 pi of Reverse Transcriptase (RETROscript™) to transcribe
cDNA. This reaction was incubated at 44°C for one hour. The reaction was
stopped by incubating at 92°C for 10 minutes. A PCR was performed using the
primers 659R and 40F as described above and the product was sent to the
Murdock Molecular Biology Laboratory for sequencing.
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Figure 4. The pBSV2RII plasmid used as a cloning vector for the SPR3 16S
rRNA gene. The 16S rRNA gene from SPR3 with the Cl 186U mutation was
cloned into the EcoRl site in the multiple cloning site. The plasmid was
transformed into B. burgdorferi strain B31-F to test for spectinomycin-resistance
of the resulting merodiploid.
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Aminoglycoside Susceptibility. A susceptibility assay was done to
determine the level of resistance of the KanR mutant. Culture tubes were “set up”
the same way as the spectinomycin experiment with the following concentrations
in pg/ml of kanamycin: 0,160, 320,400, 640, 800,960 and 1120. After 72 hours
the cells were centrifuged, resuspended in dPBS++, and an ODeoo was taken to
determine the I C 5 0 . Susceptibility assays were also performed to test for cross
resistance to spectinomycin, streptomycin, and gentamicin. Again, 106 cells of
the mutant were added to 4 ml of BSK, grown for 72 hours at 34°C with the
following concentrations in pg/ml added to individual tubes: spectinomycin, 0,
0.015, 0.03, 0.06, 0.15, 0.3, 0.6, 1.5; streptomycin, 0, 0.7, 1.8, 3.5, 7, 18, 35, 70;
and gentamicin, 0, 0.6, 1.5, 3, 6, 15, 30, 60. The amount o f gentamicin used in
this assay was increased to 0,120,180,240, 300, 360,480, and 600 as a result of
the resistance at lower levels. To determine the increase in resistance to both
kanamycin and gentamicin, a wild type B31-A culture was assayed at the
following concentrations in pg/ml: kanamycin; 0, 0 .8 ,2 ,4 , 8,20,40, 80;
gentamicin; 0, 0.6,1.5, 3, 6,15, 30, 60; and streptomycin; 0, 0.7,1.8, 3.5, 7,18,
35, 70.
Susceptibility assays of the two streptomycin-resistant mutants SmR3
(K88R) and SmR4 (K88E) were performed as described with the following
concentrations in pg/ml of streptomycin: 0, 70, 140, 210, 280, 350, 420, and 490.
Susceptibility assays were also done to test for cross-resistance to the other three
antibiotics.
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Coumermycin Ai Susceptibility. A susceptibility assay, as described for
the other antibiotic-resistant mutants, was performed on each of the coumermycin
Ai-resistant T162 mutants to determine the level of resistance (IC50 ). These assays
included a naturally occurring T162I mutant that was previously isolated (D.S.
Samuels, unpublished data). B. burgdorferi strain B31-A was also assayed to
determine the wild-type level of resistance to coumermycin A i. The
concentrations in pg/ml of coumermycin Ai added to the B31-A cultures were: 0,
0.01, 0.025, 0.05,0.1, 0.25, and 0.5. 1.0. Because coumermycin Ai is dissolved
in DMSO, the protocol was modified to add equal amounts of DMSO to each
culture tube in the assay, but not to exceed 1% (40 pi) of the total volume. At
high levels o f coumermycin Ai, the culture tubes had to be vortexed and warmed
to 34° C to prevent coumermycin Ai from precipitating out of solution. Each
culture in the assay was grown to 107 to 108 cells/ml before an OD 6 0 0 was taken,
which took 4-6 days. The identified mutants were assayed for coumermycin Ai
resistance at levels found in Table 2.

2.3 Metabolism of Antibiotic-Resistant Mutants
Competition Assays. An in vivo competition assay between wild-type
B31-A and the mutant antibiotic resistant strains similar to the experiment done
by Moine et al. was performed (79). Cultures of B. burgdorferi strains B31-A,
SPR3, SPR6, SmR4 and KanR/GenR were grown, without selection, in 10 ml of
BSK to a cell density of 108 cells/ml. The concentration of cells was determined
by a spectrophotometry reading at ODeoo- From these cultures, approximately 105
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cells o f each strain were added to 10 ml of BSK to make the following nine
different cultures: B31-A, SPR3, SPR6, SmR4, KanR/GenR, B31-A+SPR3, B31A+SPR6, B31-A+SmR4, andB31-A+KanR/GenR. After mixing, approximately
103 cells from each culture were plated using techniques already described to
evaluate the number o f cells in each culture at the beginning of the assay. The
o

cultures were incubated for 96 hours until a cell density o f about 10 cells was
reached. Each time growth reached 108 cells/ml (96 hours) another 105cells were
passed into 10 ml o f BSK. Cultures were passed 10 times, or ~ 100 generations.
Three o f the experiments included plating cultures at 5 passages in addition to the
five sets of plates that were made after 10 passages to determine if the mutants
were still present with wild-type strain B31-A after 50 generations. At the end of
the assay, 103 cells from each of the nine different cultures were plated into semi
solid BSK medium with no antibiotic and in BSK plates with the appropriate
antibiotic to screen for the ratio o f antibiotic-resistant colonies to the wild-type.
The first two sets o f competition assay experiments were plated using the same
method described above for plating B31-A on plates with spectinomycin,
streptomycin and kanamycin to search for strains resistant to these antibiotics
(74). The last two competition assays were plated using the following technique
(80): Two parts BSK were added to one part 2% agarose after equilibrating both
at 55°C. 15 ml o f the BSK-agarose medium was pipetted onto 100 mm plates.
After this layer solidified, 20 ml of molten media at 42°C was mixed with the
appropriate B. burgdorferi strain and pipetted on top of the solidified 15 ml. An
example of the procedure for adding cells to both methods of plating was as
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follows: 103 cells of SPR3, SPR6, B31-A + SPR3 and B31-A + SPR6 cultures
were plated with no antibiotic or with 30 pg/ml spectinomycin to determine the
number o f spectinomycin mutants relative to the wild-type. This was done with
each strain on plates without selection and on plates with their respective
antibiotic. The plates were incubated for two weeks at 34°C at which time the
colonies on each plate were counted. This experiment was repeated five times.
At the end o f the last growth assay, 20 colonies were picked from the B31A+SPR3 plate with no selection and 20 colonies were picked from the B31A+SPR6 plate with no selection. Each of these colonies was added to one of the
wells in a 24-well culture dish containing 2 ml BSK with 30 pg/ml of
spectinomycin. SPR3 mutants were added to three of the wells in the B31A+SPR3 dish for a positive control and no cells were added to one o f the wells to
serve as a negative control. SPR6 mutants were added to three o f the wells in the
B31-A+SPR6 dish and one well had no cells added. A color change from red to
yellow caused by an increase in acidity from the metabolic activity of the B.
burgdorferi strains was used to determine if the well was positive or negative for
spectinomycin- resistant mutants.
Growth Assay. A simple growth assay was performed to determine the
doubling time of the respective mutants compared to wild-type B31-A (81). As
with the competition assay, each of the strains (B31-A, SPR3, SPR6, SmR4, and
KanR/GenR) was grown in 10 ml of BSK until a concentration o f 108 cells/ml
was reached. From these cultures, 106 cells of each strain were added to separate
tubes containing 50 ml of BSK. Every 24 hours for three days, 10 ml of each
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culture were removed and an OD6 0 0 was taken to determine the number of
cells/ml. The doubling time, when cells were in exponential growth phase, was
calculated using the following equation for the growth between day 1 and 2:
T ,-T i
log2 C2/Ci
Where, T2 - Ti represents the time difference between day 2 and day 1, which was
24 hours. C2/Ci represents the concentration of cells on day 2 and day 1. This
procedure was repeated three times. The growth rates were plotted using
SigmaPlot®, and a student’s t-test using SigmaPlot ®was performed to evaluate
the significance o f the differences in doubling times of each strain.
A growth assay was done to determine the doubling time of the
coumermycin Ai-resistant mutants following the same procedure described for
the spectinomycin and aminoglycoside-resistant mutants.
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Table 2. Concentrations of coumermycin Ai used in susceptibility assays for each
T162 mutant.
Mutation

Coumermycin A i pg/ml

T162I

0 ,1 ,2 , 5,10,25, 50,100

T162M

0, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0

T162F

0, 50,100,150,200,300,400, 500

T162S

0, 0.25, 0.5,1.0, 2.5, 5.0, 10,25

T162L

0,10, 25, 50, 100,150, 200, 250
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Chapter 3
Spectinomycin-Resistant and Aminoglycoside-Resistant Mutants

3.1 Identification and Characterization of Spectinomycin-Resistance Mutants
In an effort to develop a new selectable marker for manipulating the B.
burgdorferi genome, Frank et al. discovered a high frequency of background
mutants on 1.5 pg/ml spectinomycin plates, which precluded using the antibiotic
for selection (77). A number of other bacteria have been identified with
mutations conferring spectinomycin resistance so we hypothesized that B.
burgdorferi strain B31-A may harbor a large subpopulation with the same type of
mutation. With this knowledge we set out to identify and characterize the source
of the large number of spectinomycin-resistant mutants.
Spectinomycin Mutation Frequency. The frequency of the
spectinomycin-resistant mutants was determined by plating B. burgdorferi in
three different concentrations of spectinomycin: 1.5 pg/ml, 6.0 pg/ml and 30
pg/ml which are 7,29 and 143-fold higher than the concentration that inhibits
Q

7

growth o f the wild-type by 50%. 10 and 10 strain B31-A cells were plated at
each of these concentrations and colonies typically appeared within 11 days.
R
When 10 B31-A cells were plated, an average o f 572, 694, and 514 colonies
•

grew in spectinomycin concentrations o f 1.5, 6.0 and 30 pg/ml, respectively.

Similar results were achieved when 107 cells were plated, producing an average of
69, 62 and 62 colonies in 1.5 ,6 .0 and 30 pg/ml spectinomycin, respectively.

These procedures were repeated at least four times with the results shown in

38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 3. The frequency of spectinomycin mutants in the B. burgdorferi
population is ~ 6 x 10‘6.
To test the hypothesis that there was a high rate of mutation that confers
resistance to spectinomycin, three spectinomycin plates were inoculated with 108
cells o f a recently isolated clone, the kanamycin and gentamicin-resistant mutant
(KanR/GenR), with a known 16S rRNA sequence that did not include a mutation
specific for spectinomycin-resistance (Figure 5). No colonies grew on any of the
three plates inoculated with KanR/GenR mutants suggesting that the high
frequency o f spectinomycin-resistant mutants was due to a large subpopulation
and not a high mutation rate. Therefore, we hypothesized the mutant had a low
fitness cost so that it would be maintained in the population.
Identification of the Spectinomycin-Resistant Mutations.
Spectinomycin-resistant mutations have been mapped to the 16S rRNA gene in
other bacteria (11,13). Using this information we sequenced the 16S rRNA gene
in seven of the spectinomycin-resistant mutants to determine the mechanism of
resistance. Results of the sequencing revealed that three mutants, SPR5, SPR6 and
SPR7 had an 16S rRNA gene T354C mutation resulting in a 16S rRNA AI 185G
mutation. The other four mutants, SPR1, SPR2, SPR3 and SPR4, had a G353A
16S rRNA gene mutation resulting in a Cl 186U 16S rRNA mutation (Figure 5).
The C l 192U spectinomycin-resistant mutation is homologous to the site
identified in spectinomycin-resistant E. coli and T. thermophilus (11,13), while
the AI 185G mutation is homologous to that found in C. reinhardtii (26) and has
not been previously described in bacteria. The 1185-1186 16S rRNA sites are
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located in helix 34 that can be seen in Figure 6 . The sequence reveals no
compensatory mutations at the based-paired partners G1058 (1186) and U1059
(1185) (data not shown), which correspond to E. coli sites G1064 and U1065. The
rpsE gene encoding the S5 protein was also sequenced and no mutations were
found at sites 60-66 where spectinomycin-resistant mutations are typically found
(Figure 7) (11, 24).
Antibiotic Resistance. Susceptibility assays with wild-type B. burgdorferi
strain B31-A, SPR3 (Cl 186U), and SPR6 (A1185G) revealed that both mutations
confer a high level of resistance to spectinomycin. The IC5 0 for wild-type B.
burgdorferi is 0.2 pg/ml spectinomycin. The Cl 186U mutant, SPR3, has an IC5 0
of -300 pg/ml for a 1500-fold increase in resistance to spectinomycin. The
A1185G mutant, SPR6 , has an IC5 0 greater than 500 pg/ml, making it >2500
times more resistant than the wild-type (Figure

8

and Table 4).

SPR3 and SPR6 show no high levels of cross-resistance to related
antibiotics, streptomycin, kanamycin and gentamicin (Figures 9, 10, 11 and Table
4). The I C 5 0 for wild-type B. burgdorferi strain B31-A is 11 pg/ml, 9 pg/ml, and
2.5 pg/ml for streptomycin, kanamycin, and gentamicin, respectively.
Aminoglycoside-resistance levels for B31-A used in these assays to compare
cross-resistance were nearly identical to those reported previously (77). Both
streptomycin and kanamycin had an I C 5 0 of 7 pg/ml determined previously (77),
which is slightly lower than the 11 pg/ml and 9 pg/ml, respectively, determined in
this study (Table 4). The I C 5 0 for SPR3 was 6 pg/ml, 17 pg/ml, and 2.5 pg/ml for
streptomycin, kanamycin, and gentamicin, respectively. The I C 5 0 for SPR6 was
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9,13 and 2.5 (ig/ml, respectively, for the same set of antibiotics. The results from
all o f the antibiotic-resistance assays for SPR3 and SPR6 are summarized in Table
4.
A merodiploid was constructed to test the dominance of the
spectinomycin-resistant mutant using the pVSPR3 plasmid, constructed from
pBSV2RII and the Cl 186U mutant 16S rRNA. Sequencing this plasmid identified
no additional mutations. Because of difficulties in cloning pVSPR3 into strain
B31-A, which is the strain used throughout these experiments, a closely related
but more transformable strain, B31-F, was used. Susceptibility assays revealed no
increase in spectinomycin resistance when pVSPR3 was present in B31-F. Four
different colonies were used in the susceptibility assays of B31-F with pVSPR3
and the results from all the susceptibility assays with these plasmids are listed in
Table 5. Sequencing the cellular 16S rRNA in strain B31-F/pVSPR3 showed only
wild-type 16S rRNA present in the cell, suggesting that mutant 16S rRNA was
not being transcribed from the plasmid, which explains the lack o f a resistant
phenotype.
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Table 3. The frequency o f spectinomycin-resistant mutations in B. burgdorferi
strain B31-A (wild-type).
Mutation
Frequency

10*

Avg. No. of
Colonies
(±S.E.M.)
572 (± 83)

1.5

107

69 (± 22)

6.9 x 10'°

6.0

108

694 (± 126)

6.9 x 10'b

6.0

107

62 (± 21)

6.2 x 10'°

30

108

514 (±118)

5.1 x 10’b

30

107

62 (± 5)

6.2 x 10'6

Spectinomycin
Concentration
(pg/ml)
1.5

Number of Cells
Plated

5.7 x 10'6

The experiment was repeated four times for all spectinomycin concentrations with
the exception o f the 30 pg/ml with 108 cells, which was repeated seven times.
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Figure 5 . 16S rRNA gene sequences for seven mutant colonies picked from
spectinomycin plates and four other aminoglycoside-resistant mutants. Wild-type
B. burgdorferi strain B31-A sequence is on the top row. The DNA mutations are
a G353A in SPR 1-4 corresponding to a 16S rRNA C l 186U and a T354C
mutation in SPR 5-7 corresponding to a 16S rRNA A1185G. Kanamycin (KAN1,
3 and 4) and gentamicin (GEN2) resistant mutants have no mutations in this
region.
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Figure 6. 16S rRNA secondary structure map of the helix 34 region (boxed).
Both spectinomycin-resistant mutations are in helix 34. Modified from:
www.ma.icmb.utexas.edu/ (9)
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Figure 7. SPR1, SPR2, SPR3 and SPR6 rpsE gene sequences that encode the
ribosomal S5 protein. These spectinomycin-resistant mutants have no mutations
in the 60-66 nucleotides that are known to confer spectinomycin-resistance in
other bacteria.
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Figure 8. Spectinomycin susceptibility assay of the two mutants SPR3 (Cl 186U)
and SPR6 (A1185G). Percent growth was determined from a spectrophotometer
reading at ODeoo- Error bars represent the SEM. B31=B31-A. n = 5 for B31 and 4
for SPR3 and SPR6.
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Figure 9. Streptomycin susceptibility assays for SPR3, SPR6, and KanR/GenR.
This plot, from the susceptibility assays to determine cross-resistance to
streptomycin, shows that the spectinomycin-resistant mutants SPR3 and SPR6
and the kanamycin/gentamicin-resistant mutant KanR/GenR, are not resistant to
streptomycin. The percent growth was determined from a spectrophotometer
reading at OD 6 0 0 and the error bars represent the SEM. B31=B31-A. n = 3 for
B31 and KanR/GenR and, 6 for SPR3 and SPR6.
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Figure 10. Kanamycin susceptibility assays for SPR3 and SPR6. This graph,
from the susceptibility assays for cross-resistance to kanamycin o f the C l 186U
(SPR3) and A1185G (SPR6) shows only a slight increase in resistance to
kanamycin. The percent growth was determined from a spectrophotometer
reading at OD6 0 0 and the error bars represent the SEM. B31=B31-A. n = 3 for
B31, SPR3 and SPR6.
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Figure 11. Gentamicin susceptibility assays for SPR3 and SPR6. This graph
shows no increase in resistance to gentamicin in the SPR3 C l 186U and SPR6
A1185G mutants. The percent growth is from a spectrophotometer reading at
OD6 0 0 and the error bars represent the SEM. B31=B31-A. n = 3 for B31, SPR3
and SPR6.
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20

Table 4. The IC5 0 (pg/ml) for each of the antibiotic-resistant strains to four
antibiotics.
Strain

M utation

Sp1

Sm1 Km1 Gm 1

B31-A

None

0.22

11

9

SPR3
SPR6
KanR/GenR
SmR3

16S rRNA Cl 186U 300
16S rRNA A ll85G >500
16S rRNA A1402G 0.12
0.10
S12K88R

6
9
6
80

17
2.5
13
2.5
>800 >600
13
1.5

SmR4

S12K88E

110

16

0.08

2.5

1.5

1Antibiotics: spectinomycin (Sp), streptomycin (Sm), kanamycin (Km), and
gentamicin (Gm).
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Table 5. The susceptibility assays and resulting levels of resistance of the 16S
rRNA merodiploid.
Strain
B31-A

ICso Spectinomycin
(pg/ml)
0.2

Resistance
-

B31-F

0.2

-

B31-A + pBSV2RIIa

0.2

1

B31-F + pVSPR3b

0.2

1

aThe pBSV2RII plasmid does not have a gene for 16S rRNA.
bThe pVSPR3 plasmid contains a 16S rRNA gene with the G353A mutation
(C1186U 16S rRNA mutation).
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3.2 Identification and Characterization of Aminoglycoside Resistant Mutants
The high frequency of spectinomycin-resistant mutants identified in our
studies motivated us to examine the frequency and mechanism o f resistance to
closely related aminoglycoside antibiotics. The maintenance o f spectinomycinresistant mutants at high frequency indicates that there is a low fitness cost for
these mutants. The structurally similar aminoglycosides were tested to discover if
there is a corresponding fitness cost associated with the frequency of these
mutations. Identification o f the frequency and levels of resistance for these
mutants may also aid in choosing reliable selectable markers when working with
B. burgdorferi. Already, several markers have been constructed with
aminoglycoside resistance cassettes for identifying clones of interest (77, 78, 82).
Identifying and characterizing the frequency o f aminoglycoside resistant strains
should aid in choosing the appropriate plasmids for manipulating the Borrelia
genome.
Identification of Kanamycin and Gentamicin Resistant Mutations.
The frequency o f kanamycin resistance was determined by plating 107, 108 and
109 cells o f B. burgdorferi strain B31-A in semi-solid BSK medium containing 40
pg/ml kanamycin. Based on these results, the frequency of this mutation is
between 1.3 x 10'8 and 1.4 x 10'7. Kanamycin plates that had 108cells added
produced 3-28 colonies. 109 cells plated five times produced an average of 13
colonies per plate (ranging from 3 to 29 colonies per plate). Colonies took 14 days
to appear on the kanamycin plates, which is three days longer than the appearance
of spectinomycin-resistant colonies to appear on spectinomycin plates. Plating
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B31-A on gentamicin plates gave similar results. The frequency o f gentamicinresistant colonies was 1 x 10'8 when 109 cells were plated in 30 pg/ml of
gentamicin. Results from these experiments are compiled in Table 6.
To determine the location of the mutation that conferred resistance to
kanamycin and gentamicin, three colonies were isolated from kanamycin plates
and grown in liquid BSK medium with 40 pg/ml of kanamycin and one colony
from the gentamicin plate was grown in liquid BSK medium with 25 pg/ml
gentamicin. Sequencing of the 16S rRNA gene revealed an A1402G mutation in
each of the clones designated KAN1, KAN3, and KAN4 (Figure 12), which
corresponds to the A1408G mutation in E. coli conferring resistance to kanamycin
and gentamicin (36). Sequencing the 16S rRNA gene from a colony grown on
plates containing 30 pg/ml of gentamicin identified the same mutation, A1402G,
conferring resistance to gentamicin (Figure 12 and Table 4). The gentamicinresistant strain GEN2 has an identical 16S rRNA sequence as the kanamycinresistant strain making a single designation, KanR/GenR, convenient for the
kanamycin- and gentamicin-resistant mutant carrying the A1402G mutation.
Because the kanamycin-resistant mutants and the gentamicin-resistant mutant had
identical sequences they are represented by KanR/GenR in this paper. The
location o f the A1402G mutation is in helix 44 as shown in Figure 13.
Antibiotic Resistance. The KAN3 mutant, now designated KanR/GenR,
was assayed for susceptibility to kanamycin and the other antibiotics. The results
of this assay, which are graphed in Figure 14, reveal an IC 50 > 800 pg/ml, which
is more than 90 times the wild-type level o f resistance to kanamycin (Table 4). As
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expected a susceptibility assay revealed that the kanamycin-resistant mutant was
also cross-resistant to gentamicin at high levels. The I C 5 0 for the KanR/GenR
A1402G mutant is over 600 pg/ml of gentamicin, which is 240-fold more
resistant than wild-type B31-A (Figure 15). The I C 5 0 of the KanR/GenR mutant
in gentamicin steadily decreases to 75% of wild-type at 360 pg/ml then increases
to nearly 90% o f the wild-type at 600 pg/ml (Figure 15). The cause of this
increase in I C 5 0 is unknown.
In addition to the susceptibility assays done to determine the level of
resistance to kanamycin, assays were done to identify cross-resistance to the
antibiotics streptomycin, and spectinomycin. The assays reveal that the A1402G
mutation provides no resistance to spectinomycin or streptomycin. The I C 5 0 for
the KanR/GenR A1402G mutant is 0.12 pg/ml spectinomycin (Figure 16) and 6
pg/ml streptomycin (Figure 9), which is similar to wild-type B31-A (Table 4).
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Table 6. The frequency of aminoglycoside-resistant mutants.
Concentration
(Pg/ml)
Spectinomycin
30.0

Antibiotic

Mutation
Cells Plated Avg. Number
Colonies (± SEM)
Frequency
10s
514 (± 118)a 5.1 x 10'b

Spectinomycin

30.0

107

62.0 (± 5 )b 6.2 x 10’b

Kanamycin

40.0

10y

13.2 (± 4.3)c 1.3 x 10'*

Kanamycin

40.0

10s

14.0 (± 6) b 1.4 x 10'7

Streptomycin

35.5

10y

3.4(± 1.7)c 3.4 x 10'y

Streptomycin

35.5

10*

2.0 (± l ) c 2.0 x 10’**

Gentamicin

30.0

109

10.3 (±1.2) d 1.0 x 10'*

an = 7
bn = 4
cn = 5
dn = 3
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Figure 12. 16S rRNA gene sequences from three kanamycin-resistant mutants,
seven spectinomycin-resistant mutants and one gentamicin-resistant mutant.
Wild-type B. burgdorferi sequence is on the top row. The DNA mutation is a
T137C in KAN 1, 3 and 4, and in GEN2 corresponding to a 16S rRNA A1402G
mutation. Sequences for the four kanamycin- and gentamicin-resistant mutants are
identical for the rest o f the 16S rRNA gene.
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Identification of Streptomycin-Resistant Mutants. The frequency of
streptomycin resistance is 2.0 x 10'8 to 3.4 x 10'9, based on the number of colonies
that grew on BSK plates containing 35 pg/ml of streptomycin (Table 6). BSK
plates with 108 cells typically had one-two colonies, while plates with 109 cells
ranged from 3-9 colonies. Colonies appeared within 11 days after plating.
Sequence analysis of the four streptomycin-resistant mutants, designated
SmRl, SmR2, SmR3, and SmR4, revealed two different mutations in the rpsL
gene encoding the S12 protein (Figure 17). An A263G rpsL mutation in SmRl,
SmR2, and SmR3 resulted in a K88R substitution in the S12 protein in each of
these strains (Figure 18 and Table 4). An A262G mutation in the rpsL gene
resulted in a K88E substitution in the S12 protein of SmR4 (Figure 18 and Table
4).
Antibiotic Resistance. Susceptibility assays revealed a slight difference
in the resistance conferred by these two mutations. The IC 50 was 80 pg/ml for the
SmR3 mutant (K88R), and 110 pg/ml for the SmR4 mutant (K88E) (Figure 19
and Table 4). Complete sequencing o f the 16S rRNA gene revealed no mutations
in these streptomycin-resistant strains (data not shown). Ten different primers
were used to sequence the entire gene on both strands to identify any possible
additional mutations (Figure 4).
Susceptibility assays for spectinomycin, kanamycin, and gentamicin
showed small changes in cross-resistance for SmR3 or SmR4. These two
streptomycin-resistant mutants are slightly more susceptible to spectinomycin and
gentamicin than wild-type B31-A. The IC 50 in pg/ml of SmR3 for spectinomycin,
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kanamycin and gentamicin was 0.10,13, and 1.5, respectively. The IC 5 0 o f SmR4
for the same three antibiotics was 0.08,16 and 1.5 pg/ml, respectively. By
comparison, the IC 50 for B31-A is 0.22 pg/ml for spectinomycin, 9 pg/ml for
kanamycin and 2.5 pg/ml for gentamicin. The results from these assays are
graphed in Figures 16, 20, and 21, and listed in Table 4.
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Figure 17. Nucleotide sequence of the rpsL gene encoding the S 12 protein in
streptomycin-resistant mutants SmRl, SmR2, SmR3 and SmR4. Wild-type B31A is the top line. SmR4 has an A262G mutation and SmRl-3 have an A263G
mutation corresponding to a K88E and K88R amino acid substitution in the
ribosome S12 protein, respectively.

63

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

30
Ml * I' I
831
SMR3 M p. T. I
SMR4 M P T I

NQ I. I
NQ L I
NQ L I

R K P It K S Q 'I K K T A S P A L Q
R, K P: R K S Q Trfi:.jjt
R. K P Rf K S Q T E K

N C. .Pj

60
831

RC

I C T R V M T V T I ' K K P V S. A L R K
IC IR V M T V T P K K P N S A L R K
I C I It V M T \ I P K K P K S A L R K

SMR3 It (I
SMR4 It <:

V A.R. V . R - L S
V A R V It L. S
VA R V H L S

I

3151

88
831

i

SMR3 F
SMR4 i-

B31

t \ i

g i c; h > l g i: n s v v l i i t c t it v k
[■:v ] A Y I p C I C II N L Q K H S V V 1. 1 R G G R ^ l l t
i. v i \ v i p c. i <: ii \ i. q i: h s v v l I R C c; R’ v l
a

\ i p

I* (J \ K 1 II
g v it Y II

SMR3

p

SMR4

I*

831

k I* K \ N

SMR3
SMR4

k I* K A N

G\

K Y II

R G A K
RC \ K

RCA

K

I) T L- G V N IS It K K G R S, K- Y G .jT
I) T L C V N'N R K K G R S ■
k ;.y’ G>T
D T I. G V NN It K K (j R S K Y C T

1
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Figure 21. Gentamicin susceptibility assays for SmR3 and SmR4. The percent
growth was determined from a spectrophotometer reading at OD 6 0 0 and the error
bars represent the SEM. B31=B31-A. n = 3 for B31 and SmR4. n = 5 for SmR3.
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3.3 Competition and Growth Assays
The frequency o f spectinomycin-resistant mutants in the B31-A
population was approximately 100-fold higher than the frequency of the
aminoglycoside-resistant mutants. We hypothesized that this difference was a
result of a lower fitness cost of the SPR3 (Cl 192U) and SPR6 (A1185G)
mutations conferring spectinomycin resistance. This lower fitness cost enables
spectinomycin-resistant mutants to compete well enough with wild-type B31-A to
be maintained at frequencies higher than the typical mutation frequency observed
for most bacteria. To test this hypothesis, growth and competition assays were
done with B31-A and four of the mutants.
Growth Assays. Three independent growth assays resulted in no
significant differences in doubling time for the mutants and wild-type B31-A.
The doubling time was calculated during log phase growth that took place
between day one and day two (Figure 22). From these experiments, the doubling
time for B31-A was calculated as 7.9 hours while the doubling time was 8.8 hours
for KanR/GenR, 8.1 hours for SPR3 and SPR6, and 8.0 hours for SmR4 (Table
7). A paired t-test for each mutant versus B31-A indicates that the differences in
doubling times are not statistically significant (p= 0.53 for SPR3, 0.77 for SPR6,
0.96 for SmR4, and 0.30 for KanR/GenR, a= 0.05, Table 7).
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Table 7. Doubling time of four antibiotic-resistant mutants.
p-value

SPR3

Doubling Time (±SEM)
B31-A = 7.9 hours
8.1 (±0.3)

SPR6

8.1 (±0.1)

0.77

SmR4

8.0 (± 0.2)

0.96

KanR/GenR 8.8 (± 0.6)

0.30

Strain

0.53
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Competition Assays. At the start of each competition assay,
approximately

103

cells from each culture were plated to estimate what percent of

the competition cultures were antibiotic-resistant mutant cells compared to the
B31-A wild-type cells. The number of colonies on plates without antibiotic
selection versus plates with selection indicates that approximately equal numbers
of mutant and wild-type cells were plated (Table 8 ). Comparing the percent of
colonies that grew on selection at the beginning o f the assay and the percent of
colonies that grew on selection at the end of the assay indicates that SmR4 and
KanR/GenR were completely outgrown between 50 and 100 generations while
SPR3 and SPR6 were still present at 100 generations (Table 9).
The spectinomycin-resistant mutants cultured with B31-A fared much
better than the aminoglycoside-resistant mutants, surviving in the population for
100 generations. Comparing the number of cells from the B31-A+SPR3 cultures
plated on selection versus no selection indicates that 18% of the cells remaining
after 100 generations were SPR3. Since there is no selection for wild-type B31-A
or against SPR3 cells on the plates without selection, a test was designed to
quantify what percent of the colonies on the plates without antibiotic were SPR3.
Twenty colonies from a B31-A+SPR3 plate with no selection were picked and
grown in 2 ml BSK with 30 pg/ml spectinomycin to assess what percentage of the
colonies were SPR3 on the plate without selection. The results of this experiment
were similar to the one comparing the number of colonies on selection versus no
selection with 4 of the 20 colonies (20%) being spectinomycin-resistant. Similar
numbers were also obtained for the B31-A+SPR6 culture. Comparing the number

71

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

of colonies on spectinomycin plates versus the number of colonies on plates
without spectinomycin indicated that only 8 % of the cells in the culture were
resistant to spectinomycin (SPR6 ) after 100 generations. Picking 20 B31A+SPR6 colonies from plates with no selection and growing them in 2 ml BSK
with 30 fig/ml spectinomycin produced two spectinomycin-resistant cultures,
which yield

10

% o f the colonies in the culture that are still spectinomycin-

resistant (SPR6 ) after 100 generations. The experiment at 50 generations had
more spectinomycin-resistant mutants present than at

100

generations, as was

expected. Plating on selection versus no selection showed that 41% o f the cells
were SPR3 in the B31-A+SPR3 culture and 41% were SPR6 in the B31-A+SPR6
culture. These results are listed in Table 9.
No colonies from the B31-A+KanR/GenR culture grew on plates with
kanamycin, nor did any colonies from the B31-A+SmR4 culture appear on plates
with streptomycin after 100 generations. However, colonies from the same
cultures grew on plates with no selection indicating that wild-type B31-A was the
only cell type in the culture. Plating the B31-A+SmR4 culture at 50 generations
did produce colonies on the streptomycin plates. Two separate experiments
produced similar results indicating that 6 % of the cells in the B31-A+SmR4
culture were SmR4 at 50 generations of the competition assay. Less than one
percent o f the B31-A+KanR/GenR culture were KanR/GenR mutants at 50
generations. Two independent experiments produced only one colony each on
kanamycin plates while the two plates with no selection produced 104 and 152
colonies from the B31-A+KanR/GenR culture.
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Single cultures used as controls for the competition assays revealed that
each of the mutant strains, SPR3, SPR6 , SmR4, and KanR/GenR, grew on plates
with and without antibiotic selection after

100

generations indicating that these

cells were still viable and antibiotic-resistant (Table 10). Approximately 103 cells
were plated.
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Table 8 . The number o f colonies that grew on plates from each culture at the
beginning o f the competition assay.
No Selection (±SEM)

Strain

Selection (±SEM)
(± 0 )

B31-A

411 (±24.2)

0

SPR3

1173 (±25.7)

837 (±35.0)

SPR6

1316(±208)

1285 (±40.0)

B31-A + SPR3

1136 (±73.9)

775 (±19.2)

B31-A + SPR6

1385(±130)

1172 (±109)

SmR4

1061 (±65.8)

836 (±89.9)

B31-A + SmR4

1178 (±86.0)

862 (±70.0)

KanR/GenR

762(±114)

918(±214)

B31-A +KanR/GenR

1072 (±4.00)

1286(±138)

Spectinomycin (30 pg/ml)was the antibiotic used for selection with all SPR3 and
SPR 6 cultures, streptomycin (35 pg/ml) was the antibiotic used for all SmR4
cultures and kanamycin (40 pg/ml) was used for all KanR/GenR cultures. The
chart shows that antibiotic-resistant strains are present in large numbers in the
culture tubes at the beginning of the competition assays, n = 5.
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Table 9. The number o f antibiotic-resistant cells compared to wild-type.
100 Generations
(±SEM)
SPR3 18% (±4.4)b

Strain

50 Generations (±SEM)

B31-A + SPR3

SPR3a

41% (±4.4)a

B31-A + SPR6

SPR 6

41% (±2.1)a

SPR 6

B31-A + SmR4

SmR4

6 0

. % (±2 .0 ) c

SmR4

B31-A +KanR/GenR

KanR/GenR 0.75% (±0.25)c

8

% (±3.1)b

KanR/GenR

an = 3
bn = 4
cn = 2
dn = 5
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0% d
0% d

Table 10. The number of mutant viable colonies on plates with antibiotic and no
antibiotic selection after 1 0 0 generations.
Strain

Avg. Colonies with No
Selection (±SEM)

B31-A

234 (±119)

Avg. Colonies on
Antibiotic Selection
(±SEM)
0 (± 0 )

SPR3

821(±308)

940 (±95)

SPR6

86 6

SmR4

927 (±170)

840 (±85)

KanR/GenR

542(±132)

361 (±206)

(±189)

1079(±338)

SPR3 and SPR6 were plated in 30 pg/ml spectinomycin, SmR4 was plated in 35
pg/ml, and KanR/GenR was plated in 40 pg/ml kanamycin for selection. B31-A
was also plated in each one o f these antibiotic concentrations and no colonies
were found on the plates, n = 5

76

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Chapter 4
Coumermycin Ai-Resistant GyrB T162 Mutants

Coumermycin Ai has been used as a model for antibiotic-resistance in
Borrelia burgdorferi. This antibiotic targets DNA gyrase (67), a type II
topoisomerase that introduces negative supercoiling in DNA, which relieves
torsional stress during replication or transcription (6 8 ). Mutations in B.
burgdorferi gyrB, a subunit of DNA gyrase, that result in amino acid substitutions
at residue R133 confer resistance to coumermycin Ai (73). Lewis et al. predicted
that amino acid substitutions in E. coli GyrB T165 (homologous to T 162 in B.
burgdorferi GyrB) would result in reduced gyrase activity and resistance to
coumarin drugs (69). We performed site-directed mutagenesis to identify
mutations in B. burgdorferi gyrB resulting in amino acid substitutions at residue
T162 o f GyrB that would confer coumermycin Aj resistance but maintain GyrB
function. Characterization o f coumermycin Ai-resistant mutants at residue T162
of GyrB may further elucidate B. burgdorferi gyrase structure and function.
A naturally occurring coumermycin Ai-resistant mutant designated
CR12E, but referred to here as T162I, with a T162I substitution in GyrB was
previously isolated (D.S. Samuels, unpublished data). Sequencing revealed a C to
T substitution in gyrB changing the triplet for threonine at position 162 from ACT
to ATT, which codes for isoleucine (D.S. Samuels, unpublished data).
Susceptibility assays showed this mutant to have an IC50 for coumermycin Ai of
21 pg/ml, which is 420-fold more resistant than the wild-type (Figure 23 and
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Table 11). Four other mutants were created using random site-directed
mutagenesis targeting the codon for T162 in GyrB (B. Eggers and D.S. Samuels,
unpublished data). Several different base substitutions in the gyrB gene, TTT,
CTT, TCA, and ATG resulted in four different amino acid substitutions from
threonine to phenylalanine, leucine, serine, and methionine, respectively at
position T162. These mutants were designated T162F, T162L, T162S and
T162M. The IC 5 0 for each of these mutants was considerably higher than the
wild-type B31, which was determined to be 0.02 pg/ml and is identical to
previously reported levels of resistance for B31 (73, 83). The IC5 0 for the mutants
ranged from 0.5 pg/ml for T162S to 300 pg/ml for T162F. T162L had an IC5 0 of
200 pg/ml, T162I had an IC5 0 o f 21 pg/ml and T162M had an IC5 0 of 4.0 pg/ml
(Table 11). A plot of the T162F, T162I and T162L coumermycin Ai-resistance
assays is in Figure 23. The assays for T162S and T162M are graphed in Figure
24.
Doubling times for each of the mutants were calculated based on the log
phase growth that took place between days one and two after passage. These data
show that the mutants with the highest resistance to coumermycin Ai have the
slowest doubling times. All mutants had slower doubling times than wild-type
B31-A (7.9 hours). The T162F and T162L mutants, which were the most resistant
to coumermycin A i, had the slowest doubling times of 9.2 and 8.7 hours,
respectively. The slower growth of the T162F mutant was statistically significant
with a p-value from a t-test at 0.05. The mutants T162I, T162M, and T162S had
doubling times of 8.6, 8.6, and 8.2 hours, respectively (Table 11). Figure 25
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shows the growth of each o f the T162 mutants for three days with log phase
occurring between days one and two. Two of the doubling times for T162F were
determined from day two to three when the culture was log phase growth. Log
phase growth in these two experiments did not occur until day two.
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Figure 23. Coumermycin Ai susceptibility assay of three T162 mutants. The
percent growth was determined from a spectrophotometer reading at ODeoo and
the error bars represent the SEM. n = 5.
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Table 11. Coumermycin Ai resistance by five GyrB T162 mutants.
Fold
Resistance

Doubling
Time Hours
(± SEM)
7.9 (± 0.5)

21

420

8.6 (± 0.3)

Phenylalanine

300

6000

9.2 (±0.1)

CTT

Leucine

200

4000

8.7 (± 0.6)

T162S

TCA

Serine

0.5

25

8.2 (± 0.3)

T162M

ATG

Methionine

4.0

80

8.6 (± 0.6)

Strain

DNA
Sequence

GyrB
Residue 162

IC 50
Oig/ml)

B31
(Wildtype)
T162I

ACT

Threonine

0.02

ATT

Isoleucine

T162F

TTT

T162L
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Figure 25. Growth curve of the GyrB T162 mutants. Growth was determined
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Chapter 5
Discussion

The high frequency of spectinomycin-resistant colonies appearing on 30
pg/ml spectinomycin plates in our laboratory (76) prompted an investigation to
identify the mechanism o f resistance. We hypothesized that mutations to the 16S
rRNA or small ribosomal subunit proteins were the cause o f spectinomycin
resistance based on previous studies in other bacteria (13,24,28, 34). We
hypothesized that the frequency of these mutants in the B. burgdorferi B31-A
population was due to a low fitness cost. We also theorized that there were other
mutants present in the population resistant to the related aminoglycoside
antibiotics. We have identified five different mutations conferring high levels of
resistance to spectinomycin, streptomycin, kanamycin or gentamicin. We have
also characterized five different coumermycin Ai-resistant mutants. One of these
mutants is naturally occurring and the other four were constructed using random
site-directed mutagenesis.

5.1 Spectinomycin Resistance
Spectinomycin is an antibiotic that prevents elongation of the polypeptide
by blocking translocation o f the peptidyl tR N A from the A -site to the P-site

during translation (11, 12, 13). Mutations at several sites including 1191-1193 in
the 16S rRNA of Escherichia coli, Thermus thermophilus, and Chlamydomonas
reinhardtii have been shown to confer resistance to spectinomycin (12,24, 26).
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These mutations provide enough instability to allow helix 34 the movement
necessary for translocation even while spectinomycin is bound (11).
We have identified AI 185G and C l 186U mutations (homologous to E.
coli AI 191 and Cl 192) in Borrelia burgdorferi 16S rRNA that confer a high level
of resistance to spectinomycin (Figure 5). Susceptibility assays show a difference
in resistance to spectinomycin by the two mutants. The Cl 186U mutant has an
IC5 0 o f 300 pg/ml compared with an IC5 0 well over 500 pg/ml for the AI 185G
mutant (Table 4). Sequencing the 16S rRNA gene revealed no other mutations,
including the complementary portion of helix 34 at sites 1057-1058 (E . coli 10631064). In addition, no mutations were found in the rpsE gene encoding the S5
protein, a site of spectinomycin-resistant mutations in other bacteria (Figure 7).
The absence o f a second mutation in these genes suggests that the difference in
susceptibility o f the two mutants to spectinomycin is due to the different
nucleotide sites that were mutated. This also suggests that the mutants are not
spectinomycin-dependent. Secondary mutations in Bacillus subtilis and E. coli
have been shown to confer spectinomycin dependence when more than one
mutation occurs in the 16S rRNA or when there is a mutation in the S5 protein in
addition to a mutation in the 16S rRNA (84, 85). This lack o f dependence was
confirmed by the ability of SPR3 and SPR6 to grow in the absence of
spectinomycin (Table 8).
The 1500-fold increase in resistance to spectinomycin by the C l 186U
mutation is similar to the resistance levels reported for Salmonella enterica, which
is more than 500-fold resistant to spectinomycin when a homologous mutation is
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present (86). Resistance levels conferred by plasmid-borne 16S rRNA C l 192U
mutation in E. coli have been measured at a more modest 16-fold increase (87).
This difference is probably due to the seven wild-type 16S rRNA genes still
present in E. coli.
O f more interest is the AI 185G mutation that confers over 2500-fold
resistance to spectinomycin. A homologous mutation has been identified in the
chloroplast of the eukaryote C. reinhardtii (AI 123G, E. coli 1191) and confers a
high level of resistance to spectinomycin (26). Why the AI 185G mutation confers
more resistance than the adjacent Cl 186U mutation is perplexing. There are no
other bacterial mutations at this site (E. coli 1191) to compare resistance levels
with an 1192 mutation. Mutations deeper in helix 34 have been hypothesized to
confer more resistance to spectinomycin than those that are closer to the surface
(88). This may be due to conformational changes that disrupt the right side of
helix 34 and provide the flexibility needed in helix 34 for normal ribosomal
function when spectinomycin is bound (11, 88). This model arises from
experiments that show a Nicotiana G1193A mutation that caused a 30% reduction
in protein synthesis in 80 gg/ml spectinomycin while a G1064A mutation, which
is deeper in the helix, had only 5% reduced activity (88). This seems plausible if
AI 185 in B. burgdorferi is deeper in the helix than Cl 186 (11). The homologous
site in T. thermophilus appears to be deeper in the 30S subunit based on 16S
rRNA models from high resolution crystallography (11). Another factor
determining the level of resistance is the specific base substitution as well as the
site o f the substitution. For example, a Cl 192A mutation confers low levels of
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resistance to spectinomycin in E. coli whereas a C l 192 to G or U resulted in high
levels o f resistance (24). The data in this study demonstrate that a G substitution
provides more resistance at site 1185 than a U substitution at 1186 in B.
burgdorferi. The wild-type base at the homologous site in Euglena gracilis, and
the blue-green algae Anacystis is a C at position 1141 and 1132, respectively (89,
90). The wild-type C instead of a U in 16S rRNA in both o f these organisms
provides natural resistance to spectinomycin. However, Euglena is 20-fold more
resistant to spectinomycin than Anacystis (88). Fromm et al. hypothesized that
species-specific interactions with spectinomycin and the translocation machinery
are likely sources o f the differences observed in levels of resistance (88). All of
these factors, the position of the base substitution on helix 34, the particular base
at the mutated site, and the species-specific characteristics of the translational
machinery are probably involved with the observed differences in levels of
resistance between the two B. burgdorferi mutants, Cl 186U and A l 185G. The
A l 185G mutation matches the resistance levels of the KanR/GenR mutants. The
homologous kanamycin resistant E. coli A1408G mutant reduces the binding
affinity o f kanamycin and gentamicin for helix 44. The A l 185G mutation may
also reduce the binding affinity of spectinomycin to helix 34 reducing the
resulting in resistance levels similar to those of kanamycin resistant mutants.
Susceptibility assays with aminoglycosides revealed that both mutants,
SPR6 (Al 185G) and SPR3 (Cl 186U), had the same susceptibility to streptomycin
and gentamicin as wild-type B31-A. However, both were nearly twice as resistant
to kanamycin (Table 4). The small increase in resistance may be a result of slight
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global changes along the 16S rRNA that are caused by a decrease in the stability
of helix 34 (12,24). Many of the helices involved in antibiotic resistance have
been shown to interact with each other as well as several 3OS proteins during
translation (11,91,92). The decrease in stability of helix 34, which allows
movement in the head region o f 16S rRNA even while the rigid spectinomycin
molecule is bound, has been postulated to create changes in the position of helix
28, 35, 36, and the S5 protein (11). These structural changes could, in turn, cause
minor shifts in the position of other helices such as helix 27 and helix 44, which
binds kanamycin, resulting in the small increase in resistance to kanamycin. All
three helices, H27, H34 and H44 are structurally very close to each other and all
three interact with the S5 protein either directly or indirectly (11,91,92). Helix
27 stacks on helices 1 and 28 and the conformational switch that is made by H27
has been postulated to change the packing interactions between these three helices
(11,49). Because o f the helix-helix interaction between H34 and H28, any
change in the conformation o f H34 due to base substitutions may affect the
packing of the helices o f the H27 switch mechanism involving H I, H27 and H28.
One model proposes a series of switches involving H34 and H44 as a result of the
activities o f the H27 switch (11). Therefore, modifications to any o f these helices
may cause slight alterations in the functioning of the other helices that are
contacted. Slight changes in susceptibility to antibiotics due to a mutation in a
helix that is not associated with resistance to that antibiotic may be mediated
through helix-helix interactions or the S5 protein, which interacts with all three
helices involved in spectinomycin and aminoglycoside resistance.
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The frequency o f the spectinomycin-resistant phenotype is 6 x 10'6 in our
population of B. burgdorferi strain B31-A. This frequency includes both the
Cl 186U and A l 185G mutations. The frequency o f individual mutations was not
determined since both o f the mutant types appear on plates used to derive
mutation rates. Additional point mutations in the 16S rRNA gene, which have
been identified in other organisms conferring spectinomycin-resistance (12, 26,
27, 34), may contribute to the phenotypic mutation rate as well, but were not
represented in the seven mutants sequenced. The same number of recently cloned
B. burgdorferi with a known 16S rRNA gene sequence (KanR/GenR, Figures 5
and 12) were plated on spectinomycin plates and no colonies appeared. This
suggests that either the mutation frequency experiments with B31-A simply
selected for spectinomycin-resistant phenotypes already present in the population,
or that spectinomycin resistance and kanamycin /gentamicin resistance are not
compatible in B. burgdorferi. The concentration o f spectinomycin that B31-A was
exposed to and the number of cells in the culture media did not affect the
7

o

frequency o f mutants. Plating 10 or 10 cells at concentrations of 1.5,6.0, and 30
pg/ml o f spectinomycin resulted in similar numbers of colonies appearing on
plates (Table 3). This indicates that neither o f these factors affects the
spectinomycin-resistance phenotype. Similar observations were made with B.
burgdorferi N40 resistant to erythromycin suggesting that the frequency of
resistant cells was probably due to the maintenance of a small population of
erythromycin-resistant N40 B. burgdorferi in the population (14).
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The frequency of spectinomycin-resistant mutants is considerably higher
than the frequencies o f the aminoglycoside-resistant mutants also reported in this
o

study. The frequency of kanamycin-resistant mutants is approximately 1.3 x 1 0 ',
the frequency o f streptomycin mutants is 3.4 x 10'9 and gentamicin 1.0 x 10'8.
Although the methods used in our experiments are different from those of
other researchers who used methods pioneered by Luria and Delbruck (93),
Newman (94) or Lederberg and Lederberg (95), comparisons o f the mutation rates
for other organisms that have mutations conferring spectinomycin-resistance are
informative. The B. burgdorferi spectinomycin-resistant phenotypic frequency
recorded in this study is considerably higher than the spectinomycin-resistant
mutation frequency reported for E. coli and Salmonella enteritidis (96).
Spectinomycin-resistant mutants appear at a frequency of 2 x 10'9 in E. coli and 3
x 10'8 in S. enteritidis (96). The frequency of spectinomycin-resistance in 60
•

8

•

pg/ml spectinomycin is approximately 10" for Mycoplasma mycoides (97).
o

These mutation rates, along with rifampicin-resistant mutation rates of 1.2 x 10"
o

for E. coli and 2x10" for S. enteritidis, have been identified as typical random
mutation rates for bacteria (45, 96,98). Increases in mutation rates have been
identified in organisms that have defective methyl-directed DNA mismatch repair
systems, which are catalyzed by proteins encoded by the mut, dam and uvrD
genes (96, 98,99). Mutations in these genes, referred to as mutator genes, can
increase the incidence o f mutation 10-100 times (96). The increased mutation
frequency in mutator strains matches the mutation frequency for spectinomycinresistance mutants observed in our experiments with B. burgdorferi. Mutator
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genes have not been sequenced to determine if this is the cause of the increase in
mutation rate in B. burgdorferi. However, if any of these mutants were a mutator
strain we would predict that there would be an increase in resistance to all of the
antibiotics tested.
The frequency o f spectinomycin resistance in B. burgdorferi is similar to
the frequency observed for spectinomycin-dependent mutants in E. coli, which is
10'6 (85). It is lower than the 4 x 10'5 frequency for the secondary mutation in B.
subtilis that confers resistance for spectinomycin-dependent B. subtilis (84).
Although the high mutation frequencies hint at spectinomycin dependence in the
B. burgdorferi mutants, plating the SPR3 and SPR6 mutants on BSK plates with
no antibiotic produced as many colonies as plating with spectinomycin (Tables 8
and 10). There also were no secondary mutations found in the rpsE gene encoding
S5 or additional mutations in the 16S rRNA gene that would be characteristic of
this phenotype. This suggests that a secondary mutation, conferring
spectinomycin-dependence, is not present in SPR3 or SPR6 to account for the
apparently high mutation rates.
The doubling times (growth rates) for SPR3 and SPR6 were both 8.1
hours during log phase, which is not significantly different from the 7.9 hours for
B31-A. The aminoglycoside-resistant mutant doubling times, 8.0 hours for SmR4
and 8.8 hours for KanR/GenR, were also not significantly different than those of
B31-A, suggesting that there was too much variability in the data to detect the
differences. Statistically significant changes in doubling times have been found in
B31 that possess gyrB mutations although the doubling time reported by Samuels
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et al. of 10 hours for B31 was calculated over several days and not just at log
phase, which accounts for the discrepancy with the current study (73). The
difference in the doubling times between SPR3 or SPR6 and B31-A was not
statistically significant, which reflects the results found for other spectinomycinresistant organisms with mutations in 16S rRNA. Spectinomycin-resistant
ribosomes in E. coli had no effect on growth rates (79) and C l 192U mutant
ribosomes were as efficient as the wild-type in E. coli (12). There is little or no
difference between growth rates of wild-type E. coli and 16S rRNA Cl 192U
mutants (B. burgdorferi Cl 186U) (87). In this experiment, a plasmid was
constructed carrying the C l 192U mutation in a 16S rRNA gene and inserted into
E. coli. The doubling time, 42 minutes, for this spectinomycin-resistant clone
containing 80% mutant ribosomes was the same as wild-type E. coli (87). A
similar experiment was performed with Salmonella enterica where the C l 192U
mutant 16S rRNA gene was cloned into a plasmid and tested for resistance and
doubling time (86). The doubling time o f the mutant clone was 38 minutes
compared to 33 minutes for the wild-type (86).
The small and statistically insignificant differences in doubling time
among the spectinomycin-resistant mutants may not account for the reduced
numbers o f these mutants compared to B31-A in competition assays spanning 100
generations. However, SPR3 and SPR6 were better able to compete with B31-A
than either o f the aminoglycoside-resistant mutants, SmR4 and KanR/GenR.
After 100 generations of competition between B31-A and SPR3 or SPR 6,18%
and 8%, respectively, of the cells were the mutant spectinomycin-resistant type.

92

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

The increase in B31-A cells in the cultures of B31-A+SPR3 and B31-A+SPR6 is
evident from the plating data at the beginning of the assay, which show more
mutants present (Table 8), the plating data at 50 generations, which show 41% of
the cells to be SPR3 or SPR6 (Table 9), and the plating data at 100 generations
showing a further decrease in mutant cells (Table 9). In a competition assay with
wild-type E. coli and three strains that had mutations in the 16S rRNA binding
site with S8, wild-type ribosomes were able to out-compete mutants when grown
in M9 medium with glucose as the only carbon source for metabolism (79). The
doubling time of the variants was reported to be the same as wild-type, but after
30 doublings in M9 medium, 100% of the cells in the culture were wild-type E.
coli (79). However, culturing the wild-type and mutants in Luria broth (LB)
resulted in one o f the variants being as numerous as the wild-type after 30
doublings (79). These experiments suggest that frequency o f a mutant in a
population depends on the environment and the resources that are available for the
mutant. Based on these results, and the results of the competition assays with
spectinomycin- and aminoglycoside-resistant mutants in B. burgdorferi,
mutations in 16S rRNA may affect the ability o f the mutants to utilize the
resources in the culture medium as efficiently as the wild-type, resulting in
reduced ability to compete with wild-type. The high frequency of the
spectinomycin-resistant mutants (6 x 10"6) compared to the aminoglycosideresistant mutants in the B31-A population is likely the result o f the lower fitness
cost and the increased ability to compete.
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Cloning the SPR3 16S rRNA gene into the pBSV2RII plasmid and
transforming it into B. burgdorferi strain B31-F did not produce spectinomycinresistance. Sequencing cellular 16S rRNA from strain B3 l-F/pVSPR3 suggests
there is only wild-type 16S rRNA in the cell and the mutant 16S rRNA is not
being transcribed from the plasmid. This explains why the plasmid did not confer
any spectinomycin resistance. There could be several reasons for the gene not
being expressed. The gene may be missing part of the promoter element, it may
not be transcribed efficiently on the plasmid, the plasmid may be unstable, or the
wild-type 16S rRNA gene may have recombined with the plasmid.
E. coli merodiploids carrying spectinomycin-resistant and sensitive genes
have been made and characterized by other researchers (100, 101). There was no
apparent increase in resistance of heterozygous individuals carrying both resistant
and sensitive ribosomes. Unfortunately, the source of mutation conferring the
resistance was not reported (100,101). E. coli heterozygous merodiploids
carrying streptomycin-resistant rrn genes have also been shown to be recessive
(100, 101,102). A plasmid carrying a 16S rRNA gene with the Cl 192U mutation
confers high levels spectinomycin resistance in E. coli and Salmonella as
previously mentioned (86, 87). Merodiploids with plasmid Cl 192U 16S rRNA in
E. coli and Salmonella did confer spectinomycin resistance indicating the mutant
16S rRNA provides at least a cumulative effect if not a dominant one (86). In
addition to these experiments, Salmonella 16S rRNA with the C l 192U mutation
was transformed into two strains of E. coli (86). In the first experiment, E. coli
that had all seven rrn (16S rRNA) genes knocked-out was transformed with a
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plasmid carrying the Salmonella spectinomycin-resistant 16S rRNA gene. The
resulting transformants were spectinomycin-resistant. However, using an E. coli
strain with its own wild-type rrn genes and the plasmid carrying the Salmonella
spectinomycin-resistant C 1192U 16S rRNA did not provide resistance to
spectinomycin. Although Salmonella and E. coli 16S rRNA are 97% identical in
sequence (103), E. coli 16S rRNA was hypothesized to out-compete the
Salmonella mutant 16S rRNA for ribosomal proteins, transcription factors and
ribosomal assembly (86). The B. burgdorferi spectinomycin-resistant plasmidborne 16S rRNA gene is identical in sequence (with the exception o f the Cl 186U
mutation) to the wild-type, making competition for ribosomal proteins and
ribosomal assembly unlikely. The copy number of the plasmid in the cell may
factor into the amount of C l 186U 16S rRNA present and it may also be outcompeted for transcription factors by chromosomal rrn genes. The pBSV2
plasmid, from which the pBSV2RII was derived, appears to have a higher copy
number than chromosomal 16S rRNA, but the copy number for pBSV2RII is
unknown (76, 77). Furthermore, the conflicting results from E. coli studies
determining spectinomycin resistance of the heterozygous merodiploid may be a
function o f the different plasmids that were used as vectors in the individual
experiments.
There are additional factors that should be considered as well. The
difficulty in transforming B31-A with pVSPR3 may indicate that the plasmid is
not very stable. Although several plasmids with antibiotic-resistant markers have
been successfully transformed in B. burgdorferi (77), including pBSV2, there
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have been a few problems cloning and transforming plasmids in B. burgdorferi
(78). For example, the B. burgdorferi plasmid cp9 from strain N40 was
successfully cloned into pCR-XL-TOPO and reported to be quite stable.
However, when cp9 was cloned into pBluescript, the resulting plasmid was
unstable in spite of having the same origin o f replication, and similar size and
copy number as pCR-XL-TOPO (78).

5.2 Kanamycin and Gentamicin Resistance
The aminoglycosides, kanamycin and gentamicin, form several hydrogen
bonds along the major groove of helix 44 in 16S rRNA (39,41) causing
miscoding of mRNA during translation of the nascent polypeptide (36, 39).
Resistance to these antibiotics in E. coli is conferred as a result o f U1406A or
A1408G mutations in 16S rRNA that reduce the binding affinity of the antibiotic
for helix 44 (36,42).
We have identified an A1402G mutation in B. burgdorferi strain B31-A
conferring a high level o f resistance to kanamycin and gentamicin (Figure 12).
This mutation appears at a frequency of 1.3 x 10'8 on kanamycin plates and 1.0 x
10'8 on gentamicin plates, which is in the range o f frequencies considered typical
for random mutations in bacteria (47,95, 97). With an I C 5 0 > 800 pg/ml for
kanamycin and > 600 pg/ml for gentamicin, this mutation is about 100-fold or
more resistant to both antibiotics (Table 4). This high level of resistance to
kanamycin and gentamicin is also found in E. coli with the homologous A1408G
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mutation (36,42) and Mycobacterium tuberculosis with the homologous A1400G
mutation (44).
Susceptibility to the antibiotics spectinomycin and streptomycin increases
with the A1402G mutation. The IC5 0 of spectinomycin and streptomycin for the
KanR/GenR mutant is about half the IC 5 0 for wild-type B31-A (Table 4). The
increased susceptibility o f the KanR/GenR mutant to streptomycin eliminates the
possibility that this mutant carries an additional mutation that would produce a
streptomycin-dependent phenotype (59). One possibility for the observed
changes in susceptibility to these antibiotics caused by the A1402G mutation has
already been discussed regarding spectinomycin resistance. A change in
susceptibility to other antibiotics is likely due to structural changes along the 16S
rRNA that alter helix-helix interactions or increase the affinity that antibiotics
have for their binding sites. Helix 44, the site of kanamycin and gentamicin
binding, interacts directly with helices 27 and 34 (11,91). These two helices
harbor binding sites for streptomycin (H27 and H44) and spectinomycin (H34)
(11,91). Additional interactions that may be affected involve the S5 protein that
interacts with all three helices and the S12 protein that interacts with helices 27
and 44 (91, 92).
Although not statistically significant, the KanR/GenR growth rate of 8.8
hours is slower than B31-A (7.9 hours) and the other antibiotic-resistant mutants
SPR3, SPR6 and SmR4 (Table 7). The growth rate for the homologous E. coli
A1408G mutant is identical to the wild-type even with the addition o f 160 pg/ml
kanamycin (36). The E. coli A1408G mutant also does not affect ribosomal
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activity suggesting this mutant may be able to compete with wild-type E. coli (36,
42). B. burgdorferi carrying the A1402G mutation may have deleterious effects
on ribosomal function responsible for the slower growth rates. In addition to
slower growth rates, the KanR/GenR mutants were unable to compete with wildtype B31-A in competition assays. After 50 generations, less than 1% of the cells
in the B31-A+KanR/GenR culture tubes were KanR/GenR. At 100 generations,
no KanR/GenR cells were detected indicating that all of the remaining cells were
B31-A. The slower growth rate alone may account for the inability of
KanR/GenR mutants to compete with B31-A. However, the B31-A+SmR4
competition assay produced the same results despite SmR4 having a growth rate
virtually identical to B31-A, indicating there may be other metabolic factors
involved in the competition with wild-type. The frequency o f the KanR/GenR
mutant in the B31-A population may reflect how well this mutant is maintained as
well as how often the mutation arises. This scenario matches the data for mutation
frequencies and competition assays, which show SPR3 and SPR6 are more able
to compete with wild-type and, therefore, more frequent than SMR4, which is
unable to compete with wild-type and less frequent than the spectinomycinresistant mutants. It also reconciles the results of the statistical analysis that
indicate the differences in growth rates are not significant although the less
frequent mutants KanR/GenR and SmR4 do not compete as well as the
spectinomycin-resistant mutants with B31-A.

98

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

5.3 Streptomycin Resistance
Streptomycin disrupts translational accuracy by increasing the affinity for
noncognate aminoacyl tRNA molecules at the A-site and interfering with the
ability to accurately proofread during translation (45,46). This error-prone
activity is induced when streptomycin binds at several sites along the 16S rRNA
phosphate backbone and to the ribosomal S12 protein (11,47,48, 49, 50).
Mutations at several sites in the 16S rRNA gene and the rpsL gene encoding the
S12 protein have been identified as conferring resistance to streptomycin in many
organisms (47,48, 51, 52, 53, 54, 55).
We have identified two mutations in the B. burgdorferi rpsL gene
conferring resistance to streptomycin. These mutations encode K88R and K88E
amino acid substitutions in the ribosomal S12 protein. The frequency of the
O

Q

streptomycin-resistant mutations, which is between 2x10" and 3.4 x 10' for B.
burgdorferi, is in agreement with published reports (47, 96,98) for bacterial
mutation rates and similar to those for B. burgdorferi KanR/GenR. This frequency
includes both the K88R (SmR3) and K88E (SmR4) mutations and falls within the
range given for other streptomycin-resistant bacteria. The mutation frequency for
the rpsL gene in M. smegmatis is 10'8 to 10'10(47), and 2 x 10'10 for E. coli (65).
rpsL mutation frequencies in T. thermophilus are considerably higher at 10'7(62).
The frequency of K88R and K88E mutants is similar to that of the kanamycinresistant mutation and 100-fold less frequent than the spectinomycin-resistant
mutants.
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Neither mutant exhibited any of the characteristics associated with
streptomycin dependence. Complete sequencing o f the rpsL and 16S rRNA genes
revealed no secondary mutations associated with streptomycin dependence.
Another characteristic o f this phenotype is an increased resistance to kanamycin
and gentamicin. Although the level of resistance to kanamycin did increase two
fold, the SmR4 mutant was able to grow in BSK plates without streptomycin. The
ability to grow without streptomycin in the medium is not characteristic of the
streptomycin-dependent phenotype. Plates with 35 pg/ml streptomycin and plates
without streptomycin grew nearly identical numbers of SmR4 colonies indicating
that SmR4 was not dependent on streptomycin for growth in a solid medium.
The level of streptomycin-resistance was approximately 7-fold for SmR3
and 10-fold for SmR4 compared to the wild-type (Table 4). These resistance
levels are much lower than those for SPR3, SPR6 and KanR/GenR, which are all
>100-fold more resistant than wild-type to their respective antibiotics. Apparently
in B. burgdorferi, mutations in 16S rRNA gene encoding the region of
spectinomycin and kanamycin binding are able to confer much higher levels of
resistance compared to mutations located in the genes for 3OS proteins (SI2) that
interact with streptomycin. The levels of resistance in B. burgdorferi are typical of
other streptomycin-resistant mutants. Similar susceptibilities have been identified
in M. smegmatis that have the homologous mutation in rpsL encoding the S12
protein as well as in 16S rRNA (47). The S12 K88R, K88E and the 16S rRNA
530 stem loop substitutions identified in M smegmatis were all 5 to 10-fold more
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resistant to streptomycin than the wild-type (47). Anis. coli C912U substitution
conferred four-fold resistance (50).
The slight differences in streptomycin-resistance between SmR3 and
SmR4 are likely caused by a change in the electrochemical charge at residue 88 in
the S12 protein, although this difference was not observed in either M. smegmatis
or T. thermophilus (47, 62). The arginine substitution in SmR3 retains the positive
charge o f the wild-type lysine residue. In spite o f the charge remaining the same,
conformational changes in the S12 protein must occur upon substituting arginine
and its two additional side chain amino groups. The glutamic acid substitution
creates a residue at position 88 with a negatively charged side chain altering the
S12 structure from the wild-type. These changes perturb the structure of S12 and
alter the global structure of the ribosome reducing the stability of the region
around helix 27 in T. thermophilus (11, 104). The decrease in stability from the
K88R and K88E mutations may compensate for the increased stability created by
streptomycin binding and allow the ribosome to switch between the error prone
ram state and the hyper accurate restrictive state, restoring nearly normal
ribosome function while providing streptomycin resistance (11).
Susceptibility assays revealed changes in susceptibility to spectinomycin,
gentamicin, and kanamycin in both K88E and K88R strains. The two mutants
were half as resistant to spectinomycin and gentamicin and two-fold resistant to
kanamycin (Table 4). As discussed previously, these changes in susceptibility
must be due to global changes along the 16S rRNA. Several lysine and arginine
residues of T. thermophilus S12 including the homologous K88 contact helix 27
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with additional residues contacting helices 18 and 44 (11,90,104). The K88R
and K88E mutations could disrupt the S12 interactions with any of these three
helices and alter the binding affinity of spectinomycin, kanamycin or gentamicin.
S12 has been proposed to facilitate the helix 27 accuracy switch (48) that enables
the ribosome to change from the error prone ram state to the hyper accurate
proofreading state (11,48). Mutations causing modifications to the SI 2-helix 27
interaction may disrupt other helix-helix interactions as well. The helix 27 switch
may activate a series o f switches along the 16S rRNA including helix 34, which is
the site o f spectinomycin binding, and helix 44, which is the site o f kanamycin
and gentamicin binding (11). S12 also has direct contact with the upper portion of
helix 44 (91,104). The K88E and K88R substitutions may cause conformational
changes along helix 44 that alter binding affinities for kanamycin and gentamicin,
thus changing the susceptibilities to these antibiotics.
The doubling time during log phase was 8.0 hours for SmR4, which is
roughly the same as wild-type B31-A (7.9 hours). In competition assays, SmR4
was unable to compete with B31-A indicating a significant fitness cost for this
mutation. SmR4 comprised only 6% of the cell population at 50 generations and
was undetectable at 100 generations. This follows the pattern of the slower
growing KanR/GenR mutant that also had no detectable cells after 100
generations in co-culture with B31-A. The homologous A1408G 16S rRNA and
S12 mutations have been shown to affect the selection of cognate tRNAs and the
rates o f polypeptide chain elongation in E. coli and T. thermophilus (36,105,
106). Mutations in the E. coli rpsL gene slow the rates of polypeptide chain
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elongation by nearly 20% (105). A slower rate of translation could explain the
inability o f SmR4 and KanR/GenR to compete with wild-type B31-A, but should
also be accompanied by slower growth rates that are found only in the
KanR/GenR mutants. It may also help to explain why the SPR3 and SPR6
mutants are able to compete much better in competition with B31-A.
Spectinomycin-resistant mutations have been shown to have little if any affect on
ribosome function even in the absence o f antibiotic (24,25). Normal ribosome
function in SPR3 and SPR6 certainly could provide a fitness advantage that
accounts for the differences in ability to compete with B31-A among the four
mutants SPR3, SPR6, SmR4 and KanR/GenR. The decreased fitness, based on
ribosome function, for the SmR4 and KanR/GenR mutants likely explain why
they are less common in a population of B31-A than SPR3 and SPR6.
Slower translation rates should result in significantly slower growth rates.
Since SmR4 grows at the same rate as wild-type B31-A, the inability of SmR4 to
compete may be from deleterious effects on another S12 cellular role. If S 12 is a
bifunctional protein this would provide an alternative explanation for the near
normal growth, coupled with the inability of SmR4 to compete with B31-A for
resources in the medium. Another ribosomal protein, S3, is bifunctional in
Drosophila with roles in both translation and DNA repair (107), and several other
ribosomal proteins have been shown to be bifunctional as well (108,109).
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5.4 Coumermycin Ai Resistance
Coumermycin Ai is a competitive inhibitor o f the enzymatic action of
GyrB (69). Coumermycin Ai binds to GyrB at residue T165 in E. coli
(homologous to T 162 in B. burgdorferi) preventing ATP hydrolysis necessary for
the catalytic activity o f DNA gyrase (68). This reaction relieves torsional stress
caused by supercoiling resulting from transcription and replication (68).
Mutations in gyrB encoding substitutions at T165 and other residues have been
identified conferring resistance to coumermycin A] and other coumarin drugs
such as novobiocin (69, 70, 71).
We have identified one natural coumermycin Ai-resistant mutation and
four mutants generated by site-directed mutagenesis. The naturally occurring
mutant has a T162I amino acid substitution and the four site-directed mutants are
T162F, T162L, T162M and T162S. Resistance levels vary considerably for each
of the mutations and are probably a result of disrupting the water-mediated
hydrogen bond between the side chain hydroxyl group of threonine 162 and
coumermycin Ai (69). The T162I mutant is 420-fold more resistant than wild
type. This level of resistance is considerably more than reported for a Bartonella
bacilliformis T162I mutant, which was only 5-fold more resistant (71). However,
it is similar to the B. burgdorferi R133I GyrB mutation that is 300-fold more
resistant (73). As noted previously with spectinomycin resistance in E. gracilis
and Anacystis, species-specific interactions with the antibiotic could be
responsible for the observed difference in resistance (88). The least resistant of
the mutants is T162S, which is 5-fold resistant to coumermycin Aj. The side
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chain of serine is structurally similar to that of threonine. This similarity probably
allows some hydrogen bonding, or does not change the conformation of GyrB
sufficiently to interrupt the other coumermycin Ai contacts at residues G74 and
R133. In E. coli, the homologous T165S mutant does not confer resistance to
novobiocin, a structurally similar, but less potent inhibitor o f gyrase activity (67,
72,110). This may explain why mutations in E. coli R136 are the main sources of
resistance to coumermycin Ai (72). Alternatively, the reported difference in
resistance between E. coli and B. burgdorferi at this residue may be the result of
species differences in the interaction of GyrB and coumermycin Ai, or
biochemical differences between novobiocin and coumermycin Ai, which is
essentially a dimer o f novobiocin.
The T162L mutant that is 4000-fold more resistant to coumermycin Ai
than the wild-type or about ten-fold more resistant than the T162I mutant is
particularly puzzling. These two amino acids have side chain isomers that would
seem to provide a similar chemical milieu for coumermycin Ai. To further
confuse this situation, R133I and R133L mutants have these levels of resistance
reversed with R133I conferring 10-fold more resistance than R133L (B. Eggers
and D.S. Samuels, unpublished data). The T162M mutation is 80-fold resistant
and nearly matches the 100-fold resistance of an R133M mutation (B. Eggers and
D. S. Samuels, unpublished data). The most resistant of the T162 mutants is
T162F. This is likely due to the bulky aromatic ring o f the phenylalanine side
chain, and along with the nonpolar leucine (T162L) and isoleucine (T162I), lacks
the ability to form hydrogen bonds. T162F conferred resistance up to 6000-fold
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more than B31-A. A nonpolar side chain mutant T166A (.B. burgdorferi T162) in
the spirochete Brachyspira hyodysenteriae conferred coumermycin Ai resistance
400- to 500-fold over the wild-type (111), which is within the range of resistance
levels found in this study. Other nonpolar side chain mutants, the homologous E.
coli T165A and T165V, have been reported to increase the novobiocin IC 50 for
ATPase to 18 and 13-fold (110). The T173N (B. burgdorferi T 162) mutation in
Staphylococcus aureus conferred 120-fold resistance to coumermycin Ai, but
produced just two-fold resistance to novobiocin indicating that nonpolar
mutations may provide more resistance to coumermycin Ai than novobiocin (70).
These levels are considerably less than the resistance in B. burgdorferi.
The doubling time of T162F is significantly slower than B31-A, and is
probably a result o f the substitution from the polar side chain of threonine to the
nonpolar aromatic ring o f phenylalanine. The conformational changes in gyrase
resulting from this substitution would provide a logical explanation for a decrease
in gyrase function that is manifested in the slower growth rate. Substituting
residues in gyrase from charged or polar residues to nonpolar alanine residues in
E. coli has been shown to decrease activity (110). This could explain the
decreases in growth rates for the T162 mutants that have nonpolar side chains.
The slowest growing mutants, T162L (8.7 hours), T162I (8.6 hours), T162M (8.6
hours) and T162F (13.9 hours), all have nonpolar side chains that may reduce the
ATPase activity o f GyrB. This in turn could interfere with replication and
transcription associated with growth. The doubling time of B. burgdorferi
coumermycin Ai resistant R133I mutants was about 10% slower than the wild-
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type (73), which is similar to the growth rate of the T162I mutant. The growth
rate o f T162S is slightly slower than the wild-type at 8.2 hours but faster than the
nonpolar substitutions, which may be a reflection of near normal gyrase activity
resulting from the retention of a polar amino acid at residue 162.

5.6 Conclusion
Several mutations in the 16S rRNA gene and rpsL encoding 30S
ribosomal protein S12 have been identified conferring resistance to
spectinomycin, streptomycin, kanamycin or gentamicin in B. burgdorferi,
including an AI 191G (B. burgdorferi AI 185G) mutation that has not been
previously reported in bacteria. Random site-directed mutagenesis generated
additional B. burgdorferi mutants resistant to coumermycin Ai in addition to a
naturally occurring mutant.
The frequency o f spectinomycin-resistant mutants was approximately 6 x
10"6. Growth and competition assays suggest this frequency results from the
ability o f these mutants to compete with wild-type B31-A for resources. Typical
bacterial mutation rates are 100-fold lower than those for the SPR3 and SPR6
spectinomycin-resistant mutants. Mutation rates for the three aminoglycosideresistant mutants are similar to those typically reported for bacteria. Neither of
these mutants, SmR4 or KanR/GenR, competed with wild-type B31-A indicating
a higher fitness cost than the SPR3 and SPR6 mutants to maintain these mutations
in the population. Although the growth rate for SmR4 was essentially the same as
the wild type, this mutant was unable to compete with B31-A. The slower growth
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rate o f the KanR/GenR mutants is not statistically significant although it could be
a reason for the inability of this mutant to compete with B31-A. Reduced
ribosomal function, which has not been observed in homologous E. coli mutants,
may also account for the inability of this mutant to compete with wild-type B31A. The higher fitness cost measured by the inability of the KanR/GenR mutants
to compete with wild-type B31-A is likely the reason for the lower frequencies of
these mutants in the population compared to the spectinomycin-resistant mutants.
Levels of antibiotic resistance were very high for SPR3 (1500-fold), SPR6
(>2500-fold) and KanR/GenR (>100-fold) all of which had mutations in the 16S
rRNA gene. Streptomycin resistance conferred by the two S12 mutations K88R
and K88E were considerably lower at 7- and 10-fold, respectively, but were
similar to those reported for other streptomycin-resistant microorganisms. Cross
resistance in SPR3, SPR6, SmR3, SmR4 and KanR/GenR suggest each o f the
mutations cause conformational changes along the 16S rRNA that affect
interactions not associated with the respective antibiotics.
None o f the mutants exhibited an antibiotic-dependent phenotype. All had
comparable plating efficiencies and growth rates with or without antibiotic
selection.
Levels of coumermycin Ai resistance and growth rates appear to be
directly related to the side chain substitutions at residue 162 of GyrB.
Substitutions of the polar side chain of threonine to nonpolar side chains (T162F,
T162L, T162I) increase resistance to coumermycin Ai over 420-fold with the
most dramatic increase from the aromatic side chain of phenylalanine (6000-fold).
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Consistent with this observation is the substitution of serine with a polar side
chain conferring only a five-fold increase in resistance. Growth rates also
followed this pattern, with T162F being the slowest growing mutant and T162S
growing faster than the nonpolar substitutions. T162M, although possessing a
nonpolar side chain, had a growth rate equal to the wild-type B31-A. This may be
due to the unique side chain with sulfur providing resistance to coumermycin Aj,
but not inhibiting normal gyrase function.

5.7 Future Research
The experiment to determine if the spectinomycin-resistant 16S rRNA was
dominant or recessive was inconclusive. A new vector, such as pBSV2, might be
used to provide adequate expression o f the mutant gene. Ribosomal activity using
a CAT reporter/assay could be done to determine mutant ribosome activity versus
the wild-type. Reduced ribosomal activity may be responsible for the slower
growth rates and one of the fitness costs of the mutation. Footprinting of the
mutant 16S rRNA with each o f the antibiotics may confirm whether antibiotic
affinity is affected by the mutations. Spectinomycin binding affinity should be
assessed in the AI 185G 16S rRNA mutant. A more accurate evaluation of the
competition assays could be achieved by performing an RNA primer extension
from the competition cultures to measure the relative amounts of mutant 16S
rRNA versus wild-type. Additional searches should be made with infectious
strains of B. burgdorferi to see if the mutants are associated only with noninfectious strains or if they are present in all populations of B. burgdorferi. A
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dominant antibiotic-resistant mutation in an infectious strain may prove to be
clinically relevant.
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